PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32797900-4 2020 In this study, we developed a derivatization-assisted microextraction method to enhance the detection sensitivity for trace levels of a DPP-4 inhibitor, sitagliptin, from a small volume (10 muL) of human plasma by using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Sitagliptin Phosphate 153-164 dipeptidyl peptidase 4 Homo sapiens 136-141 33972682-5 2021 TKI sunitinib resistance was rescued by DPP4 inhibition using sitagliptin or specific siRNAs in RCC cells and tumors. Sitagliptin Phosphate 62-73 dipeptidyl peptidase 4 Homo sapiens 40-44 34635643-2 2021 Sitagliptin (SIT) is a DPP4 inhibitor that exerts anti-inflammatory and antioxidant effects; however, its mechanism of action in SAP-ALI remains unclear. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 23-27 34952193-11 2022 Both compounds (ZINC1572309 and the reference drug - sitagliptin) also inhibited DPP-4 activity, suggesting interesting biological effects of the selected compound at non-cytotoxic concentrations. Sitagliptin Phosphate 53-64 dipeptidyl peptidase 4 Homo sapiens 81-86 34926239-10 2021 Further, DPP4 inhibitor sitagliptin effectively inhibited cholesterol biosynthesis, reduced DHCR24 expression and enhanced MTX-induced cytotoxicity in vitro and in vivo. Sitagliptin Phosphate 24-35 dipeptidyl peptidase 4 Homo sapiens 9-13 34779087-1 2022 OBJECTIVE: To assess the efficacy and safety of DPP-4 inhibition with sitagliptin in youth with type 2 diabetes (T2D). Sitagliptin Phosphate 70-81 dipeptidyl peptidase 4 Homo sapiens 48-53 34388848-1 2021 BACKGROUND: Sitagliptin is known as an antidiabetic agent inhibiting the dipeptidyl peptidase-4. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 73-95 34635643-2 2021 Sitagliptin (SIT) is a DPP4 inhibitor that exerts anti-inflammatory and antioxidant effects; however, its mechanism of action in SAP-ALI remains unclear. Sitagliptin Phosphate 13-16 dipeptidyl peptidase 4 Homo sapiens 23-27 33151168-5 2021 Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 98-102 34484112-1 2021 Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. Sitagliptin Phosphate 99-110 dipeptidyl peptidase 4 Homo sapiens 9-30 34484112-1 2021 Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. Sitagliptin Phosphate 99-110 dipeptidyl peptidase 4 Homo sapiens 32-37 34477540-2 2022 DPP4 inhibitors (DPP4Is), also named gliptins like sitagliptin, have anti-inflammatory and antioxidant effects; thereby lessen inflammatory and oxidative stress in diabetic Covid-19 patients. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 0-4 34384428-10 2021 After MCDA, the overall value orders for each DPP-4 inhibitor included Sitagliptin (0.45), Linagliptin (0.44), Vildagliptin (0.43), Alogliptin (0.42) and Saxagliptin (0.40). Sitagliptin Phosphate 71-82 dipeptidyl peptidase 4 Homo sapiens 46-51 35635037-3 2022 Sitagliptin is an effective inhibitor of dipeptidyl peptidase 4 (DPP-4) for the treatment of diabetes, which is recently reported to regulate oxidative stress and autophagy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-63 35581701-5 2022 Sitagliptin appears to be one of the good DPP-4 inhibitors that have antiinflammatory and antithrombotic effect. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 42-47 34182806-3 2021 Utilising CV magnetic resonance imaging (CMR) and continuous glucose monitoring (CGM) by FreeStyle Libre Pro Sensor, we aim to explore the mechanisms of action which give Empagliflozin, an SGLT2 inhibitor, its beneficial CV effects and compare these to the effects of dipeptidyl peptidase-4 inhibitor Sitagliptin. Sitagliptin Phosphate 301-312 dipeptidyl peptidase 4 Homo sapiens 268-290 35388920-1 2022 The direct separation of dipeptidyl peptidase IV (DPP-4) inhibitors such as Sitagliptin (STG), Linagliptin (LIG), and Saxagliptin (SAG) enantiomers in normal phase conditions have been achieved on immobilized polysaccharide-based chiral stationary phases (CSPs), as well as on the macrocyclic glycopeptide vancomycin chiral stationary phase (Chirobiotic V2) under polar ionic mode. Sitagliptin Phosphate 76-87 dipeptidyl peptidase 4 Homo sapiens 25-48 35388920-1 2022 The direct separation of dipeptidyl peptidase IV (DPP-4) inhibitors such as Sitagliptin (STG), Linagliptin (LIG), and Saxagliptin (SAG) enantiomers in normal phase conditions have been achieved on immobilized polysaccharide-based chiral stationary phases (CSPs), as well as on the macrocyclic glycopeptide vancomycin chiral stationary phase (Chirobiotic V2) under polar ionic mode. Sitagliptin Phosphate 76-87 dipeptidyl peptidase 4 Homo sapiens 50-55 35388920-1 2022 The direct separation of dipeptidyl peptidase IV (DPP-4) inhibitors such as Sitagliptin (STG), Linagliptin (LIG), and Saxagliptin (SAG) enantiomers in normal phase conditions have been achieved on immobilized polysaccharide-based chiral stationary phases (CSPs), as well as on the macrocyclic glycopeptide vancomycin chiral stationary phase (Chirobiotic V2) under polar ionic mode. Sitagliptin Phosphate 89-92 dipeptidyl peptidase 4 Homo sapiens 25-48 35635037-3 2022 Sitagliptin is an effective inhibitor of dipeptidyl peptidase 4 (DPP-4) for the treatment of diabetes, which is recently reported to regulate oxidative stress and autophagy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 65-70 35483674-3 2022 We conducted this study to compare the serum ketone response between dapagliflozin, an SGLT2i, and sitagliptin, a dipeptidyl peptidase-4 inhibitor, among insulin-treated T2DM patients. Sitagliptin Phosphate 99-110 dipeptidyl peptidase 4 Homo sapiens 114-136 33975891-0 2021 Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 35115253-9 2022 Metformin-dipeptidyl peptidase-4 inhibitor (e.g., metformin-sitagliptin) combination was the most popular metformin-based single pill drug combination. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 10-32 35355800-7 2022 A short time after setting the beginning treatment with a basal-bolus insulin regimen, her insulin requirement rapidly declined and treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP4), was started. Sitagliptin Phosphate 147-158 dipeptidyl peptidase 4 Homo sapiens 162-184 35355800-7 2022 A short time after setting the beginning treatment with a basal-bolus insulin regimen, her insulin requirement rapidly declined and treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP4), was started. Sitagliptin Phosphate 147-158 dipeptidyl peptidase 4 Homo sapiens 196-200 35294449-1 2022 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is used orally in conjunction with diet and exercise to control sugar levels in type 2 Diabetes Mellitus patients. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 35294449-1 2022 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is used orally in conjunction with diet and exercise to control sugar levels in type 2 Diabetes Mellitus patients. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-46 34036983-4 2021 Further investigations demonstrate that the IC50 value of sitagliptin (listed as the DPP-IV inhibitor) determined with human recombinant DPP-IV (36.22 nM) is very similar to that in human plasma (39.18 nM), and sitagliptin acts as a competitive inhibitor against human plasma DPP-IV-mediated GP-BAN hydrolysis. Sitagliptin Phosphate 58-69 dipeptidyl peptidase 4 Homo sapiens 85-91 34036983-4 2021 Further investigations demonstrate that the IC50 value of sitagliptin (listed as the DPP-IV inhibitor) determined with human recombinant DPP-IV (36.22 nM) is very similar to that in human plasma (39.18 nM), and sitagliptin acts as a competitive inhibitor against human plasma DPP-IV-mediated GP-BAN hydrolysis. Sitagliptin Phosphate 58-69 dipeptidyl peptidase 4 Homo sapiens 137-143 34036983-4 2021 Further investigations demonstrate that the IC50 value of sitagliptin (listed as the DPP-IV inhibitor) determined with human recombinant DPP-IV (36.22 nM) is very similar to that in human plasma (39.18 nM), and sitagliptin acts as a competitive inhibitor against human plasma DPP-IV-mediated GP-BAN hydrolysis. Sitagliptin Phosphate 58-69 dipeptidyl peptidase 4 Homo sapiens 137-143 35320256-0 2022 Sitagliptin: A promising DPP-4 inhibitor for prevention of acute graft versus host disease. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-30 35205190-0 2022 Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin. Sitagliptin Phosphate 126-137 dipeptidyl peptidase 4 Homo sapiens 18-22 35205190-8 2022 Interestingly, our in silico molecular docking results exhibited putative binding affinities of sitagliptin with DPP4/CTNNB1/MET signatures, even higher than standard inhibitors of these genes. Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 113-117 35086469-8 2022 DPP4 inhibitors (gliptins) such as linagliptin and sitagliptin have therapeutic effects which have been shown to extend beyond glycaemic control with no risk of hypoglycaemia. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 0-4 33975891-4 2021 Therefore, we aimed to evaluate efficacy of sitagliptin, a DPP-4 inhibitor, on reducing faecal excretions in this patient group. Sitagliptin Phosphate 44-55 dipeptidyl peptidase 4 Homo sapiens 59-64 33615655-3 2021 Also, diabetic patients treated with the DPP4 inhibitor sitagliptin showed greater overall survival after colorectal or lung cancer surgery than patients under other diabetic therapies. Sitagliptin Phosphate 56-67 dipeptidyl peptidase 4 Homo sapiens 41-45 33615655-7 2021 Moreover, only invasion and motility assays, which are collagen matrix-dependent, showed a decrease upon treatment with the DPP4 inhibitor sitagliptin. Sitagliptin Phosphate 139-150 dipeptidyl peptidase 4 Homo sapiens 124-128 33615655-10 2021 At the same time, this role of sitagliptin may help to define areas of medicine where DPP4 inhibitors might be introduced. Sitagliptin Phosphate 31-42 dipeptidyl peptidase 4 Homo sapiens 86-90 33866313-1 2022 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes mellitus (T2DM), has been reported to improve psoriasis. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 27-49 33866313-1 2022 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes mellitus (T2DM), has been reported to improve psoriasis. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 51-56 33866313-2 2022 OBJECTIVE: We compared the effects of sitagliptin treatment, a DPP-4 inhibitor, in combination with narrow-band ultraviolet-B (NB-UVB) phototherapy compared to NB-UVB alone on psoriasis severity, quality of life, cardiovascular disease risk factors and immune parameters in people with moderate psoriasis without T2DM. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 63-68 33214038-6 2021 Molecular dynamics (MD) simulations following the aforementioned docking phase were performed to elucidate potential binding modes of sitagliptin"s 1,2,3-triazole analogues in hDPP-4, with the use of a cocrystal structure of hDPP-4 with sitagliptin (PDB ID: 1X70). Sitagliptin Phosphate 134-145 dipeptidyl peptidase 4 Homo sapiens 176-182 33769204-9 2021 The binding sites as well as affinity of active compounds for DPP- IV enzyme were predicted by in silico studies, and compared to a standard drug, sitagliptin. Sitagliptin Phosphate 147-158 dipeptidyl peptidase 4 Homo sapiens 62-69 32741073-9 2021 CONCLUSIONS: This meta-analysis suggested that treatment with DPP-4is, including sitagliptin, saxagliptin, and linagliptin, was associated with an increased risk of developing BP. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 62-67 33387351-7 2021 In addition, DPP4 was silenced in PTC cell lines (GLAG-66 and TPC-1) through siRNA-mediated DPP4 knockdown or sitagliptin (inhibitor of DPP4)-mediated inhibition to assess the effects of DPP4 on the MAPK pathway and cellular processes, including proliferation, apoptosis, and epithelial-to-mesenchymal transition (EMT). Sitagliptin Phosphate 110-121 dipeptidyl peptidase 4 Homo sapiens 13-17 33429063-4 2021 Patients were given the GLP-1 receptor agonist liraglutide (1.8 mg sc) or the DPP-4 inhibitor sitagliptin (100 mg), or matching placebos, once daily for 12 weeks. Sitagliptin Phosphate 94-105 dipeptidyl peptidase 4 Homo sapiens 78-83 33214038-6 2021 Molecular dynamics (MD) simulations following the aforementioned docking phase were performed to elucidate potential binding modes of sitagliptin"s 1,2,3-triazole analogues in hDPP-4, with the use of a cocrystal structure of hDPP-4 with sitagliptin (PDB ID: 1X70). Sitagliptin Phosphate 134-145 dipeptidyl peptidase 4 Homo sapiens 225-231 33214038-7 2021 Docking and MD simulations of the complexes of hDPP-4 with sitagliptin, S2 and S3 suggest that Glu205, Glu206, Tyr662, and Tyr666 would be the key amino acid residues for the binding of the molecules with the receptor. Sitagliptin Phosphate 59-70 dipeptidyl peptidase 4 Homo sapiens 47-53 33205256-0 2021 [Alopecia areata universalis under treatment with sitagliptin : Possible immunological effect of dipeptidyl peptidase-4 inhibitors?] Sitagliptin Phosphate 50-61 dipeptidyl peptidase 4 Homo sapiens 97-119 33239410-1 2020 BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. Sitagliptin Phosphate 27-38 dipeptidyl peptidase 4 Homo sapiens 42-64 32994187-2 2020 RESEARCH DESIGN AND METHODS: In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Sitagliptin Phosphate 97-108 dipeptidyl peptidase 4 Homo sapiens 139-161 33098565-2 2021 METHODS: In total, 103 patients with T2D (body mass index >= 22 kg/m2; glycated hemoglobin, 7-10%) and being treated with sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included and randomized to receive ipragliflozin or metformin. Sitagliptin Phosphate 122-133 dipeptidyl peptidase 4 Homo sapiens 137-159 33256016-4 2020 An inhibitor of dipeptidyl-peptidase 4 (DPP-4), sitagliptin, is used in diabetes treatment. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 16-38 33256016-4 2020 An inhibitor of dipeptidyl-peptidase 4 (DPP-4), sitagliptin, is used in diabetes treatment. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 40-45 33205256-1 2021 A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Sitagliptin Phosphate 97-108 dipeptidyl peptidase 4 Homo sapiens 112-134 33205256-1 2021 A 64-year old man developed alopecia universalis after one month of treatment with metformin and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Sitagliptin Phosphate 97-108 dipeptidyl peptidase 4 Homo sapiens 136-141 33163625-9 2020 Since their introduction to the market, conflicting data regarding pancreatic side effects have been published, including a small risk of developing acute pancreatitis with dipeptidyl peptidase-4 inhibitors like sitagliptin and saxagliptin. Sitagliptin Phosphate 212-223 dipeptidyl peptidase 4 Homo sapiens 173-195 32721805-12 2020 DPP4 inhibitors like sitagliptin reduce inflammation intensity in different states. Sitagliptin Phosphate 21-32 dipeptidyl peptidase 4 Homo sapiens 0-4 33224612-3 2020 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control by slowing the inactivation of incretin hormones, increasing insulin synthesis and release from pancreatic beta cells and lowering glucagon secretion from pancreatic alpha cells. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 33224612-3 2020 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control by slowing the inactivation of incretin hormones, increasing insulin synthesis and release from pancreatic beta cells and lowering glucagon secretion from pancreatic alpha cells. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-46 32721805-14 2020 Sitagliptin, an available DPP4 inhibitor drug, showed multidimensional anti-inflammatory effects among diabetic patients. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 26-30 32900698-1 2020 INTRODUCTION: Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Sitagliptin Phosphate 14-25 dipeptidyl peptidase 4 Homo sapiens 31-53 32998578-6 2022 In a nutshell, the compounds such as SNIPERSV-4 and SNIPERSV-7 have to pose good initial activity (~48%) in comparison to standard DPP-IV inhibitor (Sitagliptin). Sitagliptin Phosphate 149-160 dipeptidyl peptidase 4 Homo sapiens 131-137 32543789-5 2020 We further extended the model with a PB pharmacokinetics/pharmacodynamics model of the DPP4 inhibitor sitagliptin that allows predictions of the effects of this medication class on incretin concentrations. Sitagliptin Phosphate 102-113 dipeptidyl peptidase 4 Homo sapiens 87-91 32539832-3 2020 Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naive and sulfonylurea-treated patients with type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 32362346-1 2020 PURPOSE: Patients with type 2 diabetes mellitus require strict blood glucose control, and combination therapy with a thiazolidinedione and dipeptidyl peptidase-4 inhibitors, such as lobeglitazone and sitagliptin, is one of the recommended treatments. Sitagliptin Phosphate 200-211 dipeptidyl peptidase 4 Homo sapiens 139-161 32567544-2 2020 The present study assessed the action of the dipeptidyl peptidase-4 inhibitor sitagliptin on EPCs in newly diagnosed type 2 diabetes patients. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 45-67 32767343-5 2020 Herein, we report the case of a patient with MM and selective IgG1 deficiency who showed remarkable clinical improvement after 2-year combination therapy with the DPP-4 inhibitor sitagliptin plus vitamin D3. Sitagliptin Phosphate 179-190 dipeptidyl peptidase 4 Homo sapiens 163-168 32559768-3 2020 The aim of this meta-analysis was to evaluate the effects and safety of sitagliptin, a selective inhibitor of dipeptidyl peptidase-4 (DPP-4I), in treating NAFLD. Sitagliptin Phosphate 72-83 dipeptidyl peptidase 4 Homo sapiens 110-132 32543789-0 2020 A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin. Sitagliptin Phosphate 126-137 dipeptidyl peptidase 4 Homo sapiens 111-115 32133429-0 2020 Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin". Sitagliptin Phosphate 126-137 dipeptidyl peptidase 4 Homo sapiens 100-122 32317005-4 2020 RESULTS: Our study showed a favorable effect on HbA1c concentration and a slightly unfavorable effect on serum creatinine concentration in users of the five DPP-4 inhibitors, a favorable effect on lipid metabolism in sitagliptin, vildagliptin, and alogliptin users, and a favorable effect on hepatic parameters in sitagliptin, alogliptin, and linagliptin users, in comparison of the baseline and exposure periods. Sitagliptin Phosphate 217-228 dipeptidyl peptidase 4 Homo sapiens 157-162 32317005-4 2020 RESULTS: Our study showed a favorable effect on HbA1c concentration and a slightly unfavorable effect on serum creatinine concentration in users of the five DPP-4 inhibitors, a favorable effect on lipid metabolism in sitagliptin, vildagliptin, and alogliptin users, and a favorable effect on hepatic parameters in sitagliptin, alogliptin, and linagliptin users, in comparison of the baseline and exposure periods. Sitagliptin Phosphate 314-325 dipeptidyl peptidase 4 Homo sapiens 157-162 32301442-3 2020 Sitagliptin acts as a dipeptidyl peptidase 4 inhibitor to reduce glucose level in type 2 diabetes, but its role in fibrosis of lung fibroblasts is elusive. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 22-44 32566677-8 2020 In contrast, expressions of CD29-a subunit of the fibronectin receptor-or of the tetraspanin CD9 were lower after extended treatment with the DPP-4 inhibitors; less of the CD9 was seen at the plasma membrane after prolonged exposure to sitagliptin. Sitagliptin Phosphate 236-247 dipeptidyl peptidase 4 Homo sapiens 142-147 32534505-0 2020 Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 59-64 32194335-12 2020 The most common second line drugs were DPP4 inhibitors, mainly sitagliptin, followed by the third and second generation of sulfonylureas. Sitagliptin Phosphate 63-74 dipeptidyl peptidase 4 Homo sapiens 39-43 32133430-0 2020 Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin". Sitagliptin Phosphate 138-149 dipeptidyl peptidase 4 Homo sapiens 112-134 31468664-1 2020 AIMS: To determine the effects of the dipeptidyl peptidase-4 inhibitor, sitagliptin, on gastric emptying of a high carbohydrate meal and associated glycaemic and blood pressure responses in type 2 diabetes mellitus. Sitagliptin Phosphate 72-83 dipeptidyl peptidase 4 Homo sapiens 38-60 32454763-12 2020 Patients using DPP-4 inh, especially sitagliptin, should be evaluated carefully for pancreatitis risk factors. Sitagliptin Phosphate 37-48 dipeptidyl peptidase 4 Homo sapiens 15-20 31795778-2 2020 The main aim of study was to formulate, statistically optimize and characterize the polymeric nanomicellar (PNM) formulation of DPP-4 inhibitor (sitagliptin) using natural polymer and a nonionic surfactant.Method: Response surface methodology (RSM) an experimental design was applied for optimization of nanomicelles using full central composite design. Sitagliptin Phosphate 145-156 dipeptidyl peptidase 4 Homo sapiens 128-133 31148332-1 2019 AIMS: To compare outcomes of glucagon-stimulated C-peptide tests (GSCTs) in people with latent autoimmune diabetes in adults (LADA) after a 21-month intervention with either insulin or the dipeptidyl peptidase-4 inhibitor sitagliptin. Sitagliptin Phosphate 222-233 dipeptidyl peptidase 4 Homo sapiens 189-211 31219248-1 2019 A fixed-dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2, and sitagliptin, a dipeptidyl peptidase-4 inhibitor, was developed for the treatment of patients with type 2 diabetes mellitus. Sitagliptin Phosphate 117-128 dipeptidyl peptidase 4 Homo sapiens 132-154 31444259-0 2019 DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. Sitagliptin Phosphate 17-28 dipeptidyl peptidase 4 Homo sapiens 0-5 31290617-2 2019 Sitagliptin is a dipeptidyl-peptidase-4 (DPP-4) inhibitor that has been approved for the treatment of type 2 diabetes (T2DM). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 31290617-2 2019 Sitagliptin is a dipeptidyl-peptidase-4 (DPP-4) inhibitor that has been approved for the treatment of type 2 diabetes (T2DM). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-46 31243210-11 2019 Conclusion DPP-4 inhibition with sitagliptin did not increase or decrease the EPC proportion, SDF-1alpha level, or CFR, although the glycemic control was improved. Sitagliptin Phosphate 33-44 dipeptidyl peptidase 4 Homo sapiens 11-16 31543976-1 2019 Aims: To determine if treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, can prevent stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery. Sitagliptin Phosphate 37-48 dipeptidyl peptidase 4 Homo sapiens 52-74 31444259-1 2019 Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 31164243-1 2019 Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 36-41 31164243-1 2019 Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 12-34 31018682-2 2019 The large trials evaluating the dipeptidyl peptidase-4 inhibitors sitagliptin, alogliptin and saxagliptin demonstrated safety for cardiovascular disease. Sitagliptin Phosphate 66-77 dipeptidyl peptidase 4 Homo sapiens 32-54 31182338-5 2019 We therefore hypothesized that administration of a DPP4-inhibitor (sitagliptin) would improve CRF in adults with T2D. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 51-55 31344887-1 2019 Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4, used for the treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 42-64 31275243-8 2019 Five of the DPP-4 inhibitors (sitagliptin, vildagliptin, alogliptin, saxagliptin and linagliptin) were approved by regulatory authorities and entered the market between 2006 and 2013. Sitagliptin Phosphate 30-41 dipeptidyl peptidase 4 Homo sapiens 12-17 31019154-4 2019 A combination therapy of alphaGI, miglitol, and the DPP-4 inhibitor, sitagliptin, is more effective at decreasing postprandial glucose levels than monotherapy with either miglitol or sitagliptin. Sitagliptin Phosphate 69-80 dipeptidyl peptidase 4 Homo sapiens 52-57 30609212-1 2019 AIMS: To characterize the glycaemic efficacy and safety of initiation of the dipeptidyl peptidase-4 inhibitor sitagliptin during metformin dose escalation in people with type 2 diabetes (T2D) not at glycated haemoglobin (HbA1c) goal on a sub-maximal dose of metformin. Sitagliptin Phosphate 110-121 dipeptidyl peptidase 4 Homo sapiens 77-99 31217853-4 2019 Our findings show that inhibition of DPP-4 by sitagliptin could reduce oxidative stress, increase cell viability and prevent degradation of type II collagen and aggrecan by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) induced by AGEs in human primary chondrocytes. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 37-42 31019624-1 2019 Background: Sitagliptin, the first dipeptidyl peptidase-4 inhibitor, has demonstrated efficacy and safety as monotherapy and as add-on therapy to oral antidiabetic agents or insulin. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 35-57 31105821-3 2019 Treatment with the DPP-4 inhibitor sitagliptin, a licensed drug used for the treatment of type 2 diabetes mellitus (T2DM), ameliorated H/R-induced oxidative stress by decreasing the expression of NOX-4 and restoring the intracellular level of GSH in CMECs. Sitagliptin Phosphate 35-46 dipeptidyl peptidase 4 Homo sapiens 19-24 30242726-1 2019 AIMS: The aim is to evaluate the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4-I: sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin) in patients with type 2 diabetes. Sitagliptin Phosphate 99-110 dipeptidyl peptidase 4 Homo sapiens 56-78 30393950-0 2019 Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Sitagliptin Phosphate 142-153 dipeptidyl peptidase 4 Homo sapiens 109-131 29883070-0 2019 Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial. Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 111-133 30775811-2 2019 The first DPP-4 was sitagliptin followed by several other agents in the class introduced to manage diabetes. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 10-15 30475594-9 2019 In addition, the miniature sensor was successfully applied to the detection of an AIE-based bioprobe for evaluating the activity of the dipeptidyl-peptidase 4 (DPP-4) inhibitor sitagliptin with an IC50 of 59.80 +- 3.06 nM. Sitagliptin Phosphate 177-188 dipeptidyl peptidase 4 Homo sapiens 136-158 30346099-7 2019 Single doses of 50, 100, and 200 mg sitagliptin inhibited 67.2%, 73.8%, and 81.2% of plasma DPP-4 activity over 24 hours, respectively. Sitagliptin Phosphate 36-47 dipeptidyl peptidase 4 Homo sapiens 92-97 30475594-9 2019 In addition, the miniature sensor was successfully applied to the detection of an AIE-based bioprobe for evaluating the activity of the dipeptidyl-peptidase 4 (DPP-4) inhibitor sitagliptin with an IC50 of 59.80 +- 3.06 nM. Sitagliptin Phosphate 177-188 dipeptidyl peptidase 4 Homo sapiens 160-165 31336466-19 2019 Overall, amongst oral hypoglycemic agents, the combination of metformin and DPP4 inhibitors (Vildagliptin, Sitagliptin) was being prescribed majorly i.e 16.41%. Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 76-80 33693068-5 2018 Cardiovascular outcome trials conducted so far suggest that DPP-4 inhibitors (sitagliptin, alogliptin, and saxagliptin) do not promote arteriosclerotic disease, but there may be a difference between these drugs with regard to safety for heart failure. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 60-65 30243239-3 2018 Most of the new compounds exhibited significant hypoglycemic effect alongside with DPP-4 suppression potency considering sitagliptin as a reference drug. Sitagliptin Phosphate 121-132 dipeptidyl peptidase 4 Homo sapiens 83-88 30243239-7 2018 In addition, the new compounds were docked in the active site of DPP-4 in reference to sitagliptin to rationalize the binding modes of the compounds with the amino acid residues of the enzyme. Sitagliptin Phosphate 87-98 dipeptidyl peptidase 4 Homo sapiens 65-70 30593182-1 2018 Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Sitagliptin Phosphate 80-91 dipeptidyl peptidase 4 Homo sapiens 95-117 29966149-10 2018 The results showed that concomitant administration of sitagliptin, a DPP-4 inhibitor, with the SGLT2 inhibitor yielded the best results in terms of the lowering of the HbA1c and improvement of the serum lipid profile. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 69-74 30253968-1 2018 AIM: We investigated if a dipeptidyl peptidase-4 inhibitor, sitagliptin, can prevent perioperative stress hyperglycemia in patients without prior history of diabetes mellitus undergoing general surgery. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 26-48 30019498-1 2018 AIM: To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Sitagliptin Phosphate 80-91 dipeptidyl peptidase 4 Homo sapiens 47-69 30593182-1 2018 Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Sitagliptin Phosphate 80-91 dipeptidyl peptidase 4 Homo sapiens 119-124 30104520-6 2018 A lower IC50 (0.2 microM) was obtained for sitagliptin on human serum incubated with the substrate for 24 h. Both assays were applied to assess the activity of Lup1 (LTFPGSAED) and Soy1 (IAVPTGVA) on DPP-IV. Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 200-206 30242112-7 2018 DPP4 mRNA and protein were also decreased in clinical CRPC cases, and inhibition of DPP4 with sitagliptin enhanced the growth of prostate cancer xenografts following castration. Sitagliptin Phosphate 94-105 dipeptidyl peptidase 4 Homo sapiens 84-88 30487758-7 2018 Conversely, F357 that facilitates binding of the anchor lock domain of sitagliptin in the S2 extensive subsite of DPP4 is not conserved in DPP8/9. Sitagliptin Phosphate 71-82 dipeptidyl peptidase 4 Homo sapiens 114-118 29770541-8 2018 CONCLUSIONS: This study suggests that the DPP4 inhibitor sitagliptin has a greater ability to reduce daily glucose fluctuation than the SU glibenclamide in drug-naive Japanese patients with T2DM. Sitagliptin Phosphate 57-68 dipeptidyl peptidase 4 Homo sapiens 42-46 29275488-0 2018 The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial. Sitagliptin Phosphate 59-70 dipeptidyl peptidase 4 Homo sapiens 42-47 29275488-9 2018 CONCLUSION: Switching to a small dose of sitagliptin according to the renal function in T2DM patients with renal dysfunction demonstrated the same efficacy and safety as those with other full-dose DPP-4 inhibitors, indicating a therapeutic option with a high cost performance. Sitagliptin Phosphate 41-52 dipeptidyl peptidase 4 Homo sapiens 197-202 29936573-1 2018 INTRODUCTION: To assess the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino patients with type 2 diabetes. Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 63-85 29654643-0 2018 Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Sitagliptin Phosphate 83-94 dipeptidyl peptidase 4 Homo sapiens 50-72 29654643-1 2018 AIM: To evaluate the relationship between plasma dipeptidyl-peptidase 4 (DPP-4) activity and its protection of glucagon-like peptide-1 (GLP-1) using the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 169-180 dipeptidyl peptidase 4 Homo sapiens 49-71 29654643-1 2018 AIM: To evaluate the relationship between plasma dipeptidyl-peptidase 4 (DPP-4) activity and its protection of glucagon-like peptide-1 (GLP-1) using the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 169-180 dipeptidyl peptidase 4 Homo sapiens 73-78 29654643-1 2018 AIM: To evaluate the relationship between plasma dipeptidyl-peptidase 4 (DPP-4) activity and its protection of glucagon-like peptide-1 (GLP-1) using the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 169-180 dipeptidyl peptidase 4 Homo sapiens 153-158 29654643-3 2018 RESULTS: Plasma DPP-4 activity decreased compared to baseline (placebo) with increasing doses of sitagliptin (P < .01), reaching a maximal inhibition with the 100 mg dose. Sitagliptin Phosphate 97-108 dipeptidyl peptidase 4 Homo sapiens 16-21 29654643-5 2018 CONCLUSION: Our findings suggest that the sitagliptin dose of 100 mg is sufficient to inhibit both plasma and membrane-bound DPP-4 activity, presumably also leading to complete protection of endogenous GLP-1 in patients with T2D. Sitagliptin Phosphate 42-53 dipeptidyl peptidase 4 Homo sapiens 125-130 29679391-2 2018 In addition to anti-diabetic effects, the five most widely used DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) also exert cardiovascular protective effects. Sitagliptin Phosphate 82-93 dipeptidyl peptidase 4 Homo sapiens 64-69 28931178-0 2018 The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha. Sitagliptin Phosphate 42-53 dipeptidyl peptidase 4 Homo sapiens 9-31 29655980-4 2018 Compound 4d, a novel TGR5 agonist, in combination with Sitagliptin, a DPP-4 inhibitor, has demonstrated an adequate GLP-1 secretion and glucose lowering effect in animal models, suggesting a potential clinical option in treatment of type-2 diabetes. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 70-75 29988467-1 2018 Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 27-49 29270818-6 2018 Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. Sitagliptin Phosphate 229-240 dipeptidyl peptidase 4 Homo sapiens 53-75 29199201-0 2018 Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial). Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 13-35 29199201-3 2018 The current study investigated whether the dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates dyslipidemia and hyperglycemia. Sitagliptin Phosphate 76-87 dipeptidyl peptidase 4 Homo sapiens 43-65 29511780-1 2018 PURPOSE: Sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor approved for the treatment of type 2 diabetes, is reported to be more efficacious in Indian patients than non-Indian patient population. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 24-53 29270818-6 2018 Clinical trials have demonstrated diverse effects of Dipeptidyl peptidase-4 (DPP-4) inhibitors on HF; saxagliptin showed an increased risk of HF admissions, alogliptin was associated with higher rates of new HF admissions, while sitagliptin had a neutral effect. Sitagliptin Phosphate 229-240 dipeptidyl peptidase 4 Homo sapiens 77-82 29740221-2 2018 This study has been designed to elucidate the histological improvement of NASH with the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 104-115 dipeptidyl peptidase 4 Homo sapiens 88-93 29524519-7 2018 Cell lines over-expressing SerpinB3 displayed upregulation of DPPIV/CD26, likely as a feedback mechanism, due to the DPPIV/CD26 protease activity inhibition by SerpinB3, as confirmed by the similar behavior induced by the inhibitor Sitagliptin. Sitagliptin Phosphate 232-243 dipeptidyl peptidase 4 Homo sapiens 62-67 29524519-7 2018 Cell lines over-expressing SerpinB3 displayed upregulation of DPPIV/CD26, likely as a feedback mechanism, due to the DPPIV/CD26 protease activity inhibition by SerpinB3, as confirmed by the similar behavior induced by the inhibitor Sitagliptin. Sitagliptin Phosphate 232-243 dipeptidyl peptidase 4 Homo sapiens 68-72 29524519-7 2018 Cell lines over-expressing SerpinB3 displayed upregulation of DPPIV/CD26, likely as a feedback mechanism, due to the DPPIV/CD26 protease activity inhibition by SerpinB3, as confirmed by the similar behavior induced by the inhibitor Sitagliptin. Sitagliptin Phosphate 232-243 dipeptidyl peptidase 4 Homo sapiens 117-122 29072800-1 2018 The present study was a 4-week randomized trial to assess the efficacy and safety of sitagliptin, a dipeptidyl-peptidase-4 inhibitor, in persistent or recurring type 2 diabetes after Roux-en-Y gastric bypass surgery (RYGB). Sitagliptin Phosphate 85-96 dipeptidyl peptidase 4 Homo sapiens 100-122 29946505-1 2018 Sitagliptin is an anti-diabetic medication within the dipeptidyl peptidase 4 (DPP4) inhibitor class used as a single agent or in combination therapy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 54-76 29946505-1 2018 Sitagliptin is an anti-diabetic medication within the dipeptidyl peptidase 4 (DPP4) inhibitor class used as a single agent or in combination therapy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 78-82 29138226-1 2018 Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-38 29138226-1 2018 Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 50-55 29330813-8 2018 RESULTS: Patients with T2DM who initiated treatment with sitagliptin tended to be older and were more likely to have a pre-treatment history of arrhythmia, congestive heart failure, peripheral vascular disease, renal failure, and stroke than those initiating non-DPP-4i OAHAs, with the most pronounced differences observed between patients initiating monotherapy in all three age groups. Sitagliptin Phosphate 57-68 dipeptidyl peptidase 4 Homo sapiens 263-268 28892258-7 2018 DPP-IV activity inhibition was achieved by sitagliptin. Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 0-6 28892258-12 2018 DPP-IV inhibition by sitagliptin potentiated GSIS; this was mediated by locally-produced PYY, and not GLP-1. Sitagliptin Phosphate 21-32 dipeptidyl peptidase 4 Homo sapiens 0-6 29402270-2 2018 This study aimed to evaluate the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on the longitudinal change in GSM, an index of the tissue characteristics of the carotid wall, in patients with type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 58-80 29478970-3 2018 We tested the hypothesis that dipeptidyl peptidase-4 inhibition with sitagliptin increases stimulated GH secretion, vasodilation, and tissue plasminogen activator (tPA) activity. Sitagliptin Phosphate 69-80 dipeptidyl peptidase 4 Homo sapiens 30-52 29144805-3 2018 The present study evaluated the dipeptidyl peptidase 4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant PCOS. Sitagliptin Phosphate 65-76 dipeptidyl peptidase 4 Homo sapiens 32-54 30603364-2 2018 A rapid-acting insulin secretagog, nateglinide, and a potent dipeptidyl peptidase-4 inhibitor, sitagliptin, meet such criteria. Sitagliptin Phosphate 95-106 dipeptidyl peptidase 4 Homo sapiens 61-83 29208515-9 2018 These findings suggest that DPP-4 inhibitors such as sitagliptin may be effective for treating post-gastrectomy late dumping syndrome. Sitagliptin Phosphate 53-64 dipeptidyl peptidase 4 Homo sapiens 28-33 29403571-5 2017 Sitagliptin-a dipeptidyl peptidase (DPP)-4 inhibitor-was in tier 3 in Plans A and B and in tier 2 in Plan C during the study period. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 14-42 28701284-12 2017 CONCLUSION: The most cost-effective DPP-4 Inhibitor was sitagliptin with metformin. Sitagliptin Phosphate 56-67 dipeptidyl peptidase 4 Homo sapiens 36-41 29042993-2 2017 Sitagliptin (SIT), which is a dipeptidyl peptidase-4 inhibitor, exhibited a modest beneficial effect on glycated hemoglobin levels and is capable of ameliorating renal ischemia reperfusion injury. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 30-52 29064743-0 2017 Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study. Sitagliptin Phosphate 33-44 dipeptidyl peptidase 4 Homo sapiens 0-22 29064743-3 2017 We evaluated whether dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in adjunct to metformin prevents body weight regain more effectively than metformin alone in obese polycystic ovary syndrome (PCOS) previously treated with liraglutide. Sitagliptin Phosphate 62-73 dipeptidyl peptidase 4 Homo sapiens 45-50 29299152-0 2017 High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation. Sitagliptin Phosphate 10-21 dipeptidyl peptidase 4 Homo sapiens 49-70 29299152-2 2017 We previously showed that inhibition of dipeptidylpeptidase (DPP)-4 using sitagliptin 600 mg daily was safe with encouraging results on engraftment, but inhibition was not sustained. Sitagliptin Phosphate 74-85 dipeptidyl peptidase 4 Homo sapiens 40-67 29299152-9 2017 Compared to patients previously treated with 600 mg/day, sitagliptin 600 mg every 12 hours appeared to improve engraftment, supporting the hypothesis that more sustained DPP-4 inhibition is required. Sitagliptin Phosphate 57-68 dipeptidyl peptidase 4 Homo sapiens 170-175 29299152-10 2017 In-vivo inhibition of DPP-4 using high-dose sitagliptin compares favorably with other approaches to enhance UCB engraftment with greater simplicity, and may show synergy in combination with other strategies. Sitagliptin Phosphate 44-55 dipeptidyl peptidase 4 Homo sapiens 22-27 28929327-0 2017 Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). Sitagliptin Phosphate 31-42 dipeptidyl peptidase 4 Homo sapiens 46-68 28929327-7 2017 CONCLUSION: The present pilot trial suggests that treatment of SPIDDM/LADA by sitagliptin, a DPP-4 inhibitor, may be more effective in preserving the beta-cell function than insulin treatment for at least 4 years, possibly through the immune modulatory effects of DPP-4 inhibitors. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 93-98 28929327-7 2017 CONCLUSION: The present pilot trial suggests that treatment of SPIDDM/LADA by sitagliptin, a DPP-4 inhibitor, may be more effective in preserving the beta-cell function than insulin treatment for at least 4 years, possibly through the immune modulatory effects of DPP-4 inhibitors. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 264-269 28239939-1 2017 AIMS: To evaluate the efficacy and safety of fasiglifam, an orally active G-protein-coupled receptor 40 agonist, in combination with the dipeptidyl peptidase-4 inhibitor sitagliptin, in patients with type 2 diabetes inadequately controlled with diet/exercise (+- metformin). Sitagliptin Phosphate 170-181 dipeptidyl peptidase 4 Homo sapiens 137-159 28824076-0 2017 Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma. Sitagliptin Phosphate 72-83 dipeptidyl peptidase 4 Homo sapiens 39-61 28824076-3 2017 He had begun receiving sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for diabetes mellitus three years before the hospitalization. Sitagliptin Phosphate 23-34 dipeptidyl peptidase 4 Homo sapiens 38-60 28824076-3 2017 He had begun receiving sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for diabetes mellitus three years before the hospitalization. Sitagliptin Phosphate 23-34 dipeptidyl peptidase 4 Homo sapiens 62-67 28699089-7 2017 Two recent multicenter randomized controlled clinical trials support the safety of sitagliptin, a dipeptidylpeptidase-4 inhibitor (DPP4i), in hospitalized patients, although the sample sizes were likely too small to detect CV events. Sitagliptin Phosphate 83-94 dipeptidyl peptidase 4 Homo sapiens 98-119 29264572-0 2017 Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. Sitagliptin Phosphate 103-114 dipeptidyl peptidase 4 Homo sapiens 77-99 29264572-3 2017 Objective: We tested the hypothesis that individual characteristics, sitagliptin dose, and genetic variability in DPP4 influence DPP4 activity during sitagliptin. Sitagliptin Phosphate 150-161 dipeptidyl peptidase 4 Homo sapiens 114-118 29264572-3 2017 Objective: We tested the hypothesis that individual characteristics, sitagliptin dose, and genetic variability in DPP4 influence DPP4 activity during sitagliptin. Sitagliptin Phosphate 150-161 dipeptidyl peptidase 4 Homo sapiens 129-133 29264572-7 2017 Main Outcome Measures: DPP4 activity and antigen during placebo and sitagliptin and DPP4 inhibition during sitagliptin. Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 84-88 29264572-8 2017 Results: Sitagliptin 100 mg/d was less effective at inhibiting DPP4 activity in individuals with T2DM and hypertension than in healthy controls (P = 0.001, percent inhibition). Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 63-67 29264572-10 2017 DPP4 genotypes rs2909451 TT (P = 0.02) and rs759717 CC (P = 0.02) were associated with DPP4 activity during sitagliptin. Sitagliptin Phosphate 108-119 dipeptidyl peptidase 4 Homo sapiens 0-4 29264572-10 2017 DPP4 genotypes rs2909451 TT (P = 0.02) and rs759717 CC (P = 0.02) were associated with DPP4 activity during sitagliptin. Sitagliptin Phosphate 108-119 dipeptidyl peptidase 4 Homo sapiens 87-91 29264572-11 2017 In multivariable analyses, T2DM with hypertension, sitagliptin dose, age, systolic blood pressure, DPP4 activity during placebo, and rs2909451 genotype were significantly associated with DPP4 activity during sitagliptin. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 187-191 29264572-11 2017 In multivariable analyses, T2DM with hypertension, sitagliptin dose, age, systolic blood pressure, DPP4 activity during placebo, and rs2909451 genotype were significantly associated with DPP4 activity during sitagliptin. Sitagliptin Phosphate 208-219 dipeptidyl peptidase 4 Homo sapiens 187-191 29264572-12 2017 Conclusions: Sitagliptin is less effective in inhibiting DPP4 in individuals with T2DM and hypertension than in healthy controls. Sitagliptin Phosphate 13-24 dipeptidyl peptidase 4 Homo sapiens 57-61 28790917-7 2017 In addition, sitagliptin, a strong and highly selective DPP-4 inhibitor, showed its beneficial effects on bone metabolism by improving bone mineral density, bone quality, and bone markers. Sitagliptin Phosphate 13-24 dipeptidyl peptidase 4 Homo sapiens 56-61 27502307-3 2017 Sitagliptin, a selective once-daily oral dipeptidyl peptidase-4 inhibitor, has been shown to improve glycemic control as monotherapy and in combination with other antihyperglycemic agents, including sulfonylureas and metformin. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-63 28166651-1 2017 BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control, and sitagliptin has been associated with a reduction in cardiovascular events. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 36-41 28761216-2 2017 In clinical and real-world studies, canagliflozin, an SGLT2 inhibitor, has demonstrated superior A1C lowering compared to the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 142-153 dipeptidyl peptidase 4 Homo sapiens 126-131 28516377-2 2017 Here, we investigated the influence of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on treatment-related QOL in patients with type 2 diabetes mellitus treated with insulin. Sitagliptin Phosphate 39-50 dipeptidyl peptidase 4 Homo sapiens 54-76 28058753-7 2017 In conclusion, gemigliptin and sitagliptin were more effective than glimepiride in reducing glycaemic variability as initial combination therapy with metformin in patients with type 2 diabetes, and the DPP-4 inhibition was associated with a reduction in glycaemic variability. Sitagliptin Phosphate 31-42 dipeptidyl peptidase 4 Homo sapiens 202-207 28440488-0 2017 Dipeptidyl peptidase-4 inhibitor sitagliptin prevents high glucose-induced apoptosis via activation of AMP-activated protein kinase in endothelial cells. Sitagliptin Phosphate 33-44 dipeptidyl peptidase 4 Homo sapiens 0-22 28440488-3 2017 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and extensively used in the clinical treatment of DM. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 28440488-3 2017 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and extensively used in the clinical treatment of DM. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-46 28349708-2 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin, reduce postprandial glucose concentrations in patients with type 2 diabetes. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 0-22 28349708-2 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors, like sitagliptin, reduce postprandial glucose concentrations in patients with type 2 diabetes. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 24-29 28250768-3 2017 The present study aimed to clarify whether sitagliptin, DPP-4 inhibitor, could regress carotid intima-media thickness (IMT) in insulin-treated patients with type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 56-61 28065853-6 2017 The results showed that sitagliptin treatment inhibited the proliferation of PBMC-PHA stimulated cells in a dose dependent manner and decreased CD26 expression by these cells, suggesting that sitagliptin may interfere in CD26 expression, dimerization and cell signaling. Sitagliptin Phosphate 24-35 dipeptidyl peptidase 4 Homo sapiens 144-148 28065853-6 2017 The results showed that sitagliptin treatment inhibited the proliferation of PBMC-PHA stimulated cells in a dose dependent manner and decreased CD26 expression by these cells, suggesting that sitagliptin may interfere in CD26 expression, dimerization and cell signaling. Sitagliptin Phosphate 24-35 dipeptidyl peptidase 4 Homo sapiens 221-225 28065853-6 2017 The results showed that sitagliptin treatment inhibited the proliferation of PBMC-PHA stimulated cells in a dose dependent manner and decreased CD26 expression by these cells, suggesting that sitagliptin may interfere in CD26 expression, dimerization and cell signaling. Sitagliptin Phosphate 192-203 dipeptidyl peptidase 4 Homo sapiens 144-148 28065853-6 2017 The results showed that sitagliptin treatment inhibited the proliferation of PBMC-PHA stimulated cells in a dose dependent manner and decreased CD26 expression by these cells, suggesting that sitagliptin may interfere in CD26 expression, dimerization and cell signaling. Sitagliptin Phosphate 192-203 dipeptidyl peptidase 4 Homo sapiens 221-225 28065853-12 2017 Our data demonstrated an immunosuppressive effect of sitagliptin on Th1, Th17 and Th2 lymphocytes differentiation that leads to the generation of regulatory TGF-beta1 secreting cells with low CD26 gene expression that may influence the state of pancreatic beta-cells and controlling DM1 patients. Sitagliptin Phosphate 53-64 dipeptidyl peptidase 4 Homo sapiens 192-196 28761576-0 2017 Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, beta-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naive or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 27-49 28761576-1 2017 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is widely used in patients with type 2 diabetes. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 27-49 27998910-1 2017 OBJECTIVE: To assess the mechanistic effects of the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide and the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin on (exocrine) pancreatic physiology and morphology. Sitagliptin Phosphate 162-173 dipeptidyl peptidase 4 Homo sapiens 145-150 27630212-1 2017 OBJECTIVE: We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i). Sitagliptin Phosphate 164-175 dipeptidyl peptidase 4 Homo sapiens 179-201 27709794-0 2017 Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 14-36 28078647-1 2017 The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia ; Glactiv ; Tesavel ; Xelevia ) is approved in more than 130 countries worldwide as monotherapy and in combination with other antihyperglycaemic drugs for the treatment of adult patients with type 2 diabetes (T2D). Sitagliptin Phosphate 37-48 dipeptidyl peptidase 4 Homo sapiens 4-26 28078647-1 2017 The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia ; Glactiv ; Tesavel ; Xelevia ) is approved in more than 130 countries worldwide as monotherapy and in combination with other antihyperglycaemic drugs for the treatment of adult patients with type 2 diabetes (T2D). Sitagliptin Phosphate 50-57 dipeptidyl peptidase 4 Homo sapiens 4-26 28932239-2 2017 Commercially available gliptin-based drugs such as sitagliptin, anagliptin, linagliptin, saxagliptin, and alogliptin were specifically developed as DPPIV inhibitors for diabetic patients. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 148-153 28093996-13 2017 Sitagliptin and vildagliptin are dipeptidyl peptidase-4 inhibitors and have no risk of hypoglycemia when used as monotherapy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 33-55 28056430-0 2017 The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer"s disease. Sitagliptin Phosphate 15-26 dipeptidyl peptidase 4 Homo sapiens 30-35 28056430-1 2017 AIMS: The present study aimed to evaluate effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4I), on cognitive functions in elderly diabetic patients with and without cognitive impairment. Sitagliptin Phosphate 52-63 dipeptidyl peptidase 4 Homo sapiens 67-89 28321057-5 2017 They were then treated with sitagliptin (a DPP-4 inhibitor) for 3 months and followed-up for 12 months. Sitagliptin Phosphate 28-39 dipeptidyl peptidase 4 Homo sapiens 43-48 28182722-9 2017 Improvements in glycemic control were statistically significantly associated with the tested DPP-4 inhibitors in the high HGI group (-2.4, -1.4, -1.2 and -2.2% [-26.2, -15.3, -13.1 and -24.0 mmol/mol] for vildagliptin, linagliptin, saxagliptin and sitagliptin, respectively) but not in the low HGI group. Sitagliptin Phosphate 248-259 dipeptidyl peptidase 4 Homo sapiens 93-98 27459721-2 2017 Endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are increased by dipeptidyl peptidase 4 inhibitor therapy (sitagliptin) may protect against beta cell apoptosis. Sitagliptin Phosphate 146-157 dipeptidyl peptidase 4 Homo sapiens 104-126 27964837-2 2017 In this study, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basal insulin with a basal-bolus insulin regimen for the management of patients with type 2 diabetes in general medicine and surgery in hospitals. Sitagliptin Phosphate 90-101 dipeptidyl peptidase 4 Homo sapiens 56-78 27832184-2 2016 We studied the interaction between DPP-4 and its inhibitor drugs (sitagliptin 1, linagliptin 2, alogliptin 3, and teneligliptin 4) quantitatively by using fragment molecular orbital calculations at the RI-MP2/cc-pVDZ level to analyze the inhibitory activities of the drugs. Sitagliptin Phosphate 66-77 dipeptidyl peptidase 4 Homo sapiens 35-40 27627981-2 2016 We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic steatosis and fibrosis in patients with type 2 diabetes. Sitagliptin Phosphate 113-124 dipeptidyl peptidase 4 Homo sapiens 74-102 27388897-1 2016 OBJECTIVES: Saxagliptin and sitagliptin are two commonly used dipeptidyl peptidase-4 (DPP-4) inhibitors. Sitagliptin Phosphate 28-39 dipeptidyl peptidase 4 Homo sapiens 62-84 27388897-1 2016 OBJECTIVES: Saxagliptin and sitagliptin are two commonly used dipeptidyl peptidase-4 (DPP-4) inhibitors. Sitagliptin Phosphate 28-39 dipeptidyl peptidase 4 Homo sapiens 86-91 28078175-3 2016 Therefore, in this study, we evaluated the effects of sitagliptin, a DPP-4 inhibitor, on coronary atherosclerosis using integrated backscatter (IB)-intravascular ultrasound (IVUS) in patients with type 2 diabetes. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 69-74 27905912-1 2016 BACKGROUND: To investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood glucose control in patients with type 2 diabetes mellitus who were previously untreated with or who have a poor responsive to existing antidiabetic drugs. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 69-91 27742728-3 2016 NCT00790205, clinicaltrials.gov) participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase 4 inhibitor, according to baseline estimated glomerular filtration rate (eGFR). Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 122-144 27885251-8 2016 CONCLUSIONS The dipeptidyl peptidase-4 inhibitor sitagliptin can delay postprandial increases in glucose levels and hypotensive episodes, as well as sympathetic nervous system abnormalities and orthostatic hypotension. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 16-38 27809848-3 2016 As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness. Sitagliptin Phosphate 86-97 dipeptidyl peptidase 4 Homo sapiens 69-74 27624168-1 2016 BACKGROUND: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. Sitagliptin Phosphate 90-101 dipeptidyl peptidase 4 Homo sapiens 105-127 27759084-7 2016 In HepG2 cells, vildagliptin, M20.7, and sitagliptin - another DPP-4 inhibitor - induced S100A9 mRNA. Sitagliptin Phosphate 41-52 dipeptidyl peptidase 4 Homo sapiens 63-68 27321385-1 2016 The dipeptidyl peptidase-4 inhibitors vildagliptin and sitagliptin are effective in treating patients with type 2 diabetes mellitus. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 4-26 27338508-0 2016 Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records. Sitagliptin Phosphate 112-123 dipeptidyl peptidase 4 Homo sapiens 94-99 27338508-3 2016 Of the 4 DPP-4 inhibitors used, we focused on sitagliptin as it had the best time-response relationships. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 9-14 27388675-1 2016 AIM: To assess intraindividually the effects of DPP-IV inhibition on the subpopulations of immune cells in type 2 diabetes mellitus (DM2) patients during the course of treatment with sitagliptin. Sitagliptin Phosphate 183-194 dipeptidyl peptidase 4 Homo sapiens 48-54 27491324-3 2016 Sitagliptin is an oral dipeptidyl peptidase-IV inhibitor that preserves existing beta cell function and increases beta cell mass. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 23-46 27388675-5 2016 RESULTS: The blood plasma DPP-IV enzymatic activity was effectively inhibited during the sitagliptin treatment. Sitagliptin Phosphate 89-100 dipeptidyl peptidase 4 Homo sapiens 26-32 27464858-3 2016 The synthetic GLP-1 RA exenatide, the human GLP-1 RA liraglutide, and the DPP-4 inhibitor sitagliptin are the first agents in their respective classes to be approved for the treatment of T2D and their efficacy and safety has been studied extensively in clinical trials. Sitagliptin Phosphate 90-101 dipeptidyl peptidase 4 Homo sapiens 74-79 27151177-1 2016 BACKGROUND & AIMS: Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase and liver histology in non-alcoholic fatty liver disease (NAFLD) patients. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 70-75 27512877-8 2016 In contrast, in PD patients (n = 85), HbA1c was reduced more after 3 months of treatment with sitagliptin compared with vildagliptin and linagliptin (-1.58 +- 0.95, -0.46 +- 0.98, -0.04 +- 1.22, respectively, P = 0.001).There was no significant difference in the glucose-lowering effect between the different DPP-4 inhibitors tested in ESRD patients. Sitagliptin Phosphate 94-105 dipeptidyl peptidase 4 Homo sapiens 309-314 27326345-9 2016 CONCLUSION: Plasma fasting active GLP-1 is an independent predictive marker for the efficacy of dipeptidyl peptidase 4 inhibitor sitagliptin. Sitagliptin Phosphate 129-140 dipeptidyl peptidase 4 Homo sapiens 96-118 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. Sitagliptin Phosphate 30-41 dipeptidyl peptidase 4 Homo sapiens 0-4 26524980-0 2016 [Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease: The case of sitagliptin]. Sitagliptin Phosphate 87-98 dipeptidyl peptidase 4 Homo sapiens 1-23 27485843-1 2016 UNLABELLED: We present the results of an independent, drug company-unsupported follow-up of patients with type 2 diabetes mellitus (T2DM) treated with the dipeptidyl peptidase 4 inhibitor sitagliptin. Sitagliptin Phosphate 188-199 dipeptidyl peptidase 4 Homo sapiens 155-177 27076180-9 2016 Sitagliptin was the most preferred DPP-4 inhibitor. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 35-40 27114254-0 2016 Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus. Sitagliptin Phosphate 63-74 dipeptidyl peptidase 4 Homo sapiens 46-51 27114254-1 2016 INTRODUCTION: A 12-week prospective study was previously performed to assess the effect of add-on therapy with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes mellitus (T2DM) receiving insulin treatment. Sitagliptin Phosphate 111-122 dipeptidyl peptidase 4 Homo sapiens 126-148 27114254-1 2016 INTRODUCTION: A 12-week prospective study was previously performed to assess the effect of add-on therapy with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes mellitus (T2DM) receiving insulin treatment. Sitagliptin Phosphate 111-122 dipeptidyl peptidase 4 Homo sapiens 150-155 27137491-3 2016 Participants were treated daily with 100 mg sitagliptin, a clinically approved DPP4 inhibitor. Sitagliptin Phosphate 44-55 dipeptidyl peptidase 4 Homo sapiens 79-83 26687195-2 2016 The objective of this cohort study was to thus evaluate the cardiovascular outcome in diabetic patients who received DPP-4 inhibitors (Sitagliptin). Sitagliptin Phosphate 135-146 dipeptidyl peptidase 4 Homo sapiens 117-122 28718546-3 2016 The objective of the study was to assess the effect of sitagliptin a (DPP-4 inhibitor) oral antidiabetic drug on blood sugar, body weight, blood pressure and dyslipidaemia in type 2 diabetic patients. Sitagliptin Phosphate 55-68 dipeptidyl peptidase 4 Homo sapiens 70-75 27222674-1 2016 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an effective oral antidiabetic agent as both monotherapy and when combined with insulin. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 27-49 25794984-4 2016 Therefore, this study will be performed to evaluate the effects of sitagliptin, a DPP-4 inhibitor, on coronary atherosclerosis in patients with type 2 diabetes. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 82-87 26872429-8 2016 To investigate whether the observed effects could be attributed to the enzymatic activity of DPP4, human adipocytes were treated with the DPP4 inhibitors sitagliptin and saxagliptin. Sitagliptin Phosphate 154-165 dipeptidyl peptidase 4 Homo sapiens 93-97 27190600-2 2016 Taking advantage of X-ray cocrystal structures of sitagliptin and other DPP-4 inhibitors, such as alogliptin and linagliptin bound to DPP-4, and aided by molecular modeling, we designed several series of heterocyclic compounds as initial targets. Sitagliptin Phosphate 50-61 dipeptidyl peptidase 4 Homo sapiens 134-139 26826382-8 2016 Following the overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Linagliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity between the two gliptins could explain their diverse effects on endothelial cell biology. Sitagliptin Phosphate 171-182 dipeptidyl peptidase 4 Homo sapiens 37-42 26925169-1 2016 BACKGROUND: The 52-week monotherapy with the dipeptidyl peptidase-4 inhibitor sitagliptin and the sulphonylurea glimepiride on early-phase insulin secretion in Japanese patients with type 2 diabetes mellitus (T2DM) is not known. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 45-67 26822324-2 2016 We assessed the effects of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on carotid intima-media thickness (IMT) in T2DM. Sitagliptin Phosphate 27-38 dipeptidyl peptidase 4 Homo sapiens 42-64 26826382-4 2016 In the cell-free system, both Linagliptin and Sitagliptin inhibited recombinant DPP-4 activity in a concentration-dependent manner. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 80-85 26826382-8 2016 Following the overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Linagliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity between the two gliptins could explain their diverse effects on endothelial cell biology. Sitagliptin Phosphate 171-182 dipeptidyl peptidase 4 Homo sapiens 61-66 26826382-8 2016 Following the overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Linagliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity between the two gliptins could explain their diverse effects on endothelial cell biology. Sitagliptin Phosphate 171-182 dipeptidyl peptidase 4 Homo sapiens 61-66 26826382-8 2016 Following the overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Linagliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity between the two gliptins could explain their diverse effects on endothelial cell biology. Sitagliptin Phosphate 171-182 dipeptidyl peptidase 4 Homo sapiens 61-66 26826382-8 2016 Following the overexpression of pCMV-DPP-4-GFP and pCMV6-Myc-DPP-4 in endothelial cells, the proximity of Myc-DPP-4 and DPP-4-GFP was suppressed by Linagliptin but not by Sitagliptin, suggesting that only Linagliptin inhibited the homo-dimer formation of DPP-4 in endothelial cells; this difference in activity between the two gliptins could explain their diverse effects on endothelial cell biology. Sitagliptin Phosphate 171-182 dipeptidyl peptidase 4 Homo sapiens 61-66 26888822-11 2016 The pooling of adjusted estimates from observational studies similarly suggested (with very low quality evidence) a possible increased risk of admission for heart failure (adjusted odds ratio 1.41, 95% confidence interval 0.95 to 2.09) in patients treated with DPP-4 inhibitors (exclusively sitagliptin) versus no use. Sitagliptin Phosphate 291-302 dipeptidyl peptidase 4 Homo sapiens 261-266 26767505-2 2016 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 26804641-0 2016 Factors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes. Sitagliptin Phosphate 74-85 dipeptidyl peptidase 4 Homo sapiens 58-63 26767505-2 2016 Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-46 26816911-2 2015 Inhibitors of DPP-4 enzyme like Sitagliptin and Vildagliptin have shown Anti-oxidant properties in many studies, both invivo and invitro. Sitagliptin Phosphate 32-43 dipeptidyl peptidase 4 Homo sapiens 14-19 27928958-1 2016 BACKGROUND: We conducted a comparison between the dipeptidyl-peptidase-4(DPP-4) inhibitor sitagliptin versus NPH insulin as an add-on therapies in patients with type 2 diabetes mellitus (T2D) failing oral medications. Sitagliptin Phosphate 90-101 dipeptidyl peptidase 4 Homo sapiens 50-72 27928958-1 2016 BACKGROUND: We conducted a comparison between the dipeptidyl-peptidase-4(DPP-4) inhibitor sitagliptin versus NPH insulin as an add-on therapies in patients with type 2 diabetes mellitus (T2D) failing oral medications. Sitagliptin Phosphate 90-101 dipeptidyl peptidase 4 Homo sapiens 73-78 27252860-2 2016 Herein, we report a case of a young male, diagnosed with LADA based on both clinical presentation and positive anti-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) (sitagliptin) and cholecalciferol. Sitagliptin Phosphate 262-273 dipeptidyl peptidase 4 Homo sapiens 220-242 26508675-0 2015 Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 26467280-0 2015 Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus. Sitagliptin Phosphate 34-45 dipeptidyl peptidase 4 Homo sapiens 49-54 26467280-3 2015 Sitagliptin (50 mg/day), a dipeptidyl peptidase 4 (DPP-4) inhibitor that increases glucagon-like peptide 1 (GLP-1), was administered to patients with type 2 diabetes (n = 24) for 12 weeks. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 27-49 26467280-3 2015 Sitagliptin (50 mg/day), a dipeptidyl peptidase 4 (DPP-4) inhibitor that increases glucagon-like peptide 1 (GLP-1), was administered to patients with type 2 diabetes (n = 24) for 12 weeks. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 51-56 26467280-7 2015 Treatment with recombinant DPP-4 increased gene expression and long-term secretion of FABP4, and the effects were cancelled by sitagliptin. Sitagliptin Phosphate 127-138 dipeptidyl peptidase 4 Homo sapiens 27-32 26467280-9 2015 In conclusion, sitagliptin decreases serum FABP4 level, at least in part, via reduction in the expression and consecutive secretion of FABP4 in adipocytes by direct inhibition of DPP-4. Sitagliptin Phosphate 15-26 dipeptidyl peptidase 4 Homo sapiens 179-184 26195265-0 2015 Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic beta-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers. Sitagliptin Phosphate 33-44 dipeptidyl peptidase 4 Homo sapiens 0-22 26195265-8 2015 CONCLUSION: Treatment with the DPP-4 inhibitor sitagliptin might exert beneficial effects on pancreatic beta-cell function in ARB-treated T2DM patients and its efficacy might be more pronounced in hypoglycemic drug naive patients. Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 31-36 26824365-7 2016 Dipeptidyl peptidase-IV inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) are not inferior to sulfonylureas, causing significantly less hypoglycaemia and not inducing weight gain. Sitagliptin Phosphate 74-85 dipeptidyl peptidase 4 Homo sapiens 0-23 27904111-3 2016 We herein report a case that experienced restoration of a blunted HPA axis by avoiding hypoglycemia with the use of the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 136-147 dipeptidyl peptidase 4 Homo sapiens 120-125 27642611-9 2016 In conclusion DPP-4 inhibitors such as vildagliptin and sitagliptin may form a suitable glucose-lowering therapy option for Ramadan fasting patients. Sitagliptin Phosphate 56-67 dipeptidyl peptidase 4 Homo sapiens 14-19 26438107-2 2015 Dipeptidyl peptidase-4 inhibitors (DPP-4is) like sitagliptin are generally well tolerated in patients with T2DM and renal disease and therefore may be preferentially used in patients with CKD. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 0-22 26209038-0 2015 Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 26209038-6 2015 Plasma levels of SDF-1alpha and IP-10, both physiological substrates of endogenous DPP-4 and chemokines, were significantly decreased at 12 weeks of sitagliptin treatment. Sitagliptin Phosphate 149-160 dipeptidyl peptidase 4 Homo sapiens 83-88 26032047-7 2015 Compounds with smaller- or medium-sized nitrogenous bridges were comparable with sitagliptin in terms of DPP-IV inhibitory activity, potentially via targeting Glu203 and Glu204. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 105-111 26586327-9 2015 For the prolonged intervention, patients will be randomised to 12-week treatment with the GLP-1 receptor agonist liraglutide, the DPP-4 inhibitor sitagliptin or matching placebos. Sitagliptin Phosphate 146-157 dipeptidyl peptidase 4 Homo sapiens 130-135 26267432-11 2015 CONCLUSIONS AND IMPLICATIONS: DPP4 promoted EGF-induced epithelial cell transformation and mammary tumourigenesis via induction of PIN1 expression, suggesting that sitagliptin targeting of DPP4 could be a treatment strategy in patients with breast cancer. Sitagliptin Phosphate 164-175 dipeptidyl peptidase 4 Homo sapiens 30-34 26267432-11 2015 CONCLUSIONS AND IMPLICATIONS: DPP4 promoted EGF-induced epithelial cell transformation and mammary tumourigenesis via induction of PIN1 expression, suggesting that sitagliptin targeting of DPP4 could be a treatment strategy in patients with breast cancer. Sitagliptin Phosphate 164-175 dipeptidyl peptidase 4 Homo sapiens 189-193 26187356-2 2015 Several studies have shown that DPP-4 inhibitors including sitagliptin have beneficial effects in atherosclerosis and cardiac infarction involving reactive oxygen species. Sitagliptin Phosphate 59-70 dipeptidyl peptidase 4 Homo sapiens 32-37 26031638-2 2015 Although various dipeptidyl peptidase-4 inhibitors have been widely used and assumed to be administrated in many patients with psoriasis accompanied by type 2 diabetic mellitus, only two studies have shown that sitagliptin, a dipeptidyl peptidase-4 inhibitor, improved the cutaneous symptom of psoriasis independently of its antihyperglycemic effect. Sitagliptin Phosphate 211-222 dipeptidyl peptidase 4 Homo sapiens 17-39 26031638-2 2015 Although various dipeptidyl peptidase-4 inhibitors have been widely used and assumed to be administrated in many patients with psoriasis accompanied by type 2 diabetic mellitus, only two studies have shown that sitagliptin, a dipeptidyl peptidase-4 inhibitor, improved the cutaneous symptom of psoriasis independently of its antihyperglycemic effect. Sitagliptin Phosphate 211-222 dipeptidyl peptidase 4 Homo sapiens 226-248 26222679-9 2015 But in the presence of sitagliptin SiHa showed an increase in migration, indicating that, at least in part, cell migration is regulated by DPPIV/CD26 activity. Sitagliptin Phosphate 23-34 dipeptidyl peptidase 4 Homo sapiens 139-144 26198273-3 2015 Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. Sitagliptin Phosphate 159-180 dipeptidyl peptidase 4 Homo sapiens 69-91 26198273-3 2015 Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. Sitagliptin Phosphate 159-180 dipeptidyl peptidase 4 Homo sapiens 93-98 26198273-5 2015 Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Sitagliptin Phosphate 109-120 dipeptidyl peptidase 4 Homo sapiens 89-94 26073703-11 2015 Among SITA discontinuers, 44.1% switched to a preferred DPP-4 inhibitor, 9.2% switched to glucagon-like peptides-1 (GLP-1) or insulin, and 2.4% switched to metformin or sulfonylurea. Sitagliptin Phosphate 6-10 dipeptidyl peptidase 4 Homo sapiens 56-61 26301196-1 2015 BACKGROUND: This study aimed to evaluate the effect of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, on insulin secretion and glucagon suppression in Korean subjects with type 2 diabetes mellitus. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 76-98 26222679-9 2015 But in the presence of sitagliptin SiHa showed an increase in migration, indicating that, at least in part, cell migration is regulated by DPPIV/CD26 activity. Sitagliptin Phosphate 23-34 dipeptidyl peptidase 4 Homo sapiens 145-149 25938633-3 2015 Dipeptidyl peptidase-4 inhibitors (sitagliptin) improve glucose tolerance and may possess immunomodulatory effects because leukocyte CD26 cell surface receptors express dipeptidyl peptidase-4 activity. Sitagliptin Phosphate 35-46 dipeptidyl peptidase 4 Homo sapiens 0-22 25934525-1 2015 AIMS: To evaluate the effect of the DPP-4 inhibitor sitagliptin on intrahepatic lipid (IHL) content and body fat in overweight Japanese patients with type 2 diabetes. Sitagliptin Phosphate 52-63 dipeptidyl peptidase 4 Homo sapiens 36-41 26052984-1 2015 BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. Sitagliptin Phosphate 88-99 dipeptidyl peptidase 4 Homo sapiens 103-125 26191473-1 2015 AIM: To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury. Sitagliptin Phosphate 83-94 dipeptidyl peptidase 4 Homo sapiens 49-71 25938633-3 2015 Dipeptidyl peptidase-4 inhibitors (sitagliptin) improve glucose tolerance and may possess immunomodulatory effects because leukocyte CD26 cell surface receptors express dipeptidyl peptidase-4 activity. Sitagliptin Phosphate 35-46 dipeptidyl peptidase 4 Homo sapiens 169-191 26181549-1 2015 The cerebrovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) with ischemic stroke remains uncertain. Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 58-80 26312005-3 2015 Sitagliptin is the first DPP-4 inhibitor to be marketed in India. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-30 25667364-5 2015 Sitagliptin, a DPP-4 inhibitor, was a commonly used therapy for hyperglycemia after PT due to its wide availability and coverage. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 25694217-1 2015 AIMS: To assess whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin affects glucagon and other counter-regulatory hormone responses to hypoglycaemia in patients with type 1 diabetes. Sitagliptin Phosphate 69-80 dipeptidyl peptidase 4 Homo sapiens 28-50 25694217-1 2015 AIMS: To assess whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin affects glucagon and other counter-regulatory hormone responses to hypoglycaemia in patients with type 1 diabetes. Sitagliptin Phosphate 69-80 dipeptidyl peptidase 4 Homo sapiens 52-57 26115092-1 2015 BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 69-91 26115092-1 2015 BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 93-98 25667364-12 2015 CONCLUSION: Early treatment of hyperglycemia after PT with a DPP-4 inhibitor such as sitagliptin prolongs the time to insulin therapy compared with a standard observation approach. Sitagliptin Phosphate 85-96 dipeptidyl peptidase 4 Homo sapiens 61-66 25652751-3 2015 Sitagliptin, a DPP-4 inhibitor, improves glycaemic control in adult patients of all ages with T2DM, with a low risk of hypoglycaemia when used alone or in combination with other antidiabetic agents that are not generally associated with hypoglycaemia when used independently. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 26000559-1 2015 Sitagliptin, a dipeptidyl peptidase 4 inhibitor, was the first in its class to receive approval from the US FDA in 2006 for the treatment of Type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 25477187-2 2015 The effect of drug (Sitagliptin )/peptide and binary peptide mixtures on DPP-IV inhibition was studied using an isobole approach. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 73-79 25630605-2 2015 AREAS COVERED: An updated review providing an analysis of available safety data (meta-analyses, randomized controlled trials, observational cohort and case-control studies and pharmacovigilance reports) with five commercialized DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin). Sitagliptin Phosphate 246-257 dipeptidyl peptidase 4 Homo sapiens 228-233 25802724-3 2015 The present pilot study determined the effects of 12-week treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, on liver fat content in type 2 diabetes with fatty liver. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 88-110 26584290-10 2015 CONCLUSIONS: This study provides insight into the utility of the DPP-4 inhibitor sitagliptin for MSCs transplantation in the ischemic microenvironment that extends its antidiabetic property. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 65-70 25331711-4 2015 Most DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin) are predominantly excreted by the kidneys. Sitagliptin Phosphate 23-34 dipeptidyl peptidase 4 Homo sapiens 5-10 25243647-1 2015 AIMS: To examine whether 12 weeks of treatment with a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, influences the insulin secretion induced by glucose, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) during a hyperglycaemic clamp in patients with type 2 diabetes (T2DM). Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 54-76 25243647-1 2015 AIMS: To examine whether 12 weeks of treatment with a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, influences the insulin secretion induced by glucose, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) during a hyperglycaemic clamp in patients with type 2 diabetes (T2DM). Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 78-83 25243647-13 2015 CONCLUSIONS: Treatment with the DPP-4 inhibitor sitagliptin over 12 weeks in patients with T2DM partially restored the lost insulinotropic effect of GIP, whereas the preserved insulinotropic effect of GLP-1 was not further improved. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 32-37 25328079-1 2015 This study aimed to explore the effects of the dipeptidyl peptidase-4 inhibitor sitagliptin and the biguanide metformin on the secretion of insulin and glucagon, as well as incretin levels, in Japanese subjects with type 2 diabetes mellitus poorly controlled with insulin monotherapy. Sitagliptin Phosphate 80-91 dipeptidyl peptidase 4 Homo sapiens 47-69 25361590-3 2015 By an in situ enzymatic activity assay, we show an abundant DPP-IV-like enzymatic activity sensitive to a highly specific DPP-IV inhibitor sitagliptin and corresponding DPP-IV immunoreactivity in the adult human islets of Langerhans. Sitagliptin Phosphate 139-150 dipeptidyl peptidase 4 Homo sapiens 60-66 25361590-3 2015 By an in situ enzymatic activity assay, we show an abundant DPP-IV-like enzymatic activity sensitive to a highly specific DPP-IV inhibitor sitagliptin and corresponding DPP-IV immunoreactivity in the adult human islets of Langerhans. Sitagliptin Phosphate 139-150 dipeptidyl peptidase 4 Homo sapiens 122-128 25361590-3 2015 By an in situ enzymatic activity assay, we show an abundant DPP-IV-like enzymatic activity sensitive to a highly specific DPP-IV inhibitor sitagliptin and corresponding DPP-IV immunoreactivity in the adult human islets of Langerhans. Sitagliptin Phosphate 139-150 dipeptidyl peptidase 4 Homo sapiens 122-128 25597851-7 2015 The formation of M20.7 in mouse, rat, and human liver S9 fraction was inhibited by sitagliptin, a selective DPP-4 inhibitor. Sitagliptin Phosphate 83-94 dipeptidyl peptidase 4 Homo sapiens 108-113 25528312-1 2015 BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) are unclear. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 69-91 25528312-1 2015 BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) are unclear. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 93-98 25815154-2 2015 A comparison of the inhibitory activity of these compounds to the known type-2 diabetes compound (sitagliptin) against dipeptidyl peptidase-4 (DPP-4) will be shown. Sitagliptin Phosphate 98-109 dipeptidyl peptidase 4 Homo sapiens 119-141 25815154-2 2015 A comparison of the inhibitory activity of these compounds to the known type-2 diabetes compound (sitagliptin) against dipeptidyl peptidase-4 (DPP-4) will be shown. Sitagliptin Phosphate 98-109 dipeptidyl peptidase 4 Homo sapiens 143-148 26517136-0 2015 Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin. Sitagliptin Phosphate 219-230 dipeptidyl peptidase 4 Homo sapiens 87-110 25412338-3 2014 The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients. Sitagliptin Phosphate 153-164 dipeptidyl peptidase 4 Homo sapiens 114-142 25283263-7 2014 Results from ongoing large multicenter trials with the DPP-4 inhibitors sitagliptin and linagliptin are expected to clarify the potential heart failure issue related to treatment with DPP-4 inhibitors. Sitagliptin Phosphate 72-83 dipeptidyl peptidase 4 Homo sapiens 55-60 25283263-7 2014 Results from ongoing large multicenter trials with the DPP-4 inhibitors sitagliptin and linagliptin are expected to clarify the potential heart failure issue related to treatment with DPP-4 inhibitors. Sitagliptin Phosphate 72-83 dipeptidyl peptidase 4 Homo sapiens 184-189 25420579-0 2014 Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Sitagliptin Phosphate 64-75 dipeptidyl peptidase 4 Homo sapiens 31-53 25420579-1 2014 BACKGROUND: Sitagliptin inhibits dipeptidyl peptidase-4, which inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 33-55 25408522-0 2014 Effects of dipeptidyl peptidase IV inhibitor sitagliptin on immunological parameters of lymphocytes in intact animals and animals with experimental autoimmune process. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 11-34 25408522-1 2014 The effects of dipeptidyl peptidase IV inhibitor sitagliptin on immunological parameters were studied in animals with experimental autoimmune process. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 15-38 24809328-0 2014 Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. Sitagliptin Phosphate 99-110 dipeptidyl peptidase 4 Homo sapiens 68-73 24809328-6 2014 However, little is known on the molecular dynamics of DPP-4 and the interaction properties with its ligands, namely Sitagliptin and Diprotin-A. Sitagliptin Phosphate 116-127 dipeptidyl peptidase 4 Homo sapiens 54-59 24530100-1 2014 AIMS: We investigated to clarify factors associated with the efficacy of sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor, for glycemic control including the confounding effect of concomitant drugs in patients with type 2 diabetes. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 88-117 25122001-6 2014 The expression levels of hemoglobin in HEK293 and Caki-1 cells were significantly decreased when DPP4 was knocked down by siRNA, were significantly increased by the addition of soluble human DPP4, and were also significantly increased by the addition of the DPP4 inhibitor, sitagliptin. Sitagliptin Phosphate 274-285 dipeptidyl peptidase 4 Homo sapiens 97-101 25122001-7 2014 The expression level of DPP4 was also significantly increased by the addition of sitagliptin in both cell types. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 24-28 25034387-3 2014 The impact of sitagliptin, a selective inhibitor of dipeptidyl peptidase-4, on inflammation and markers of endothelial function remains to be fully characterized. Sitagliptin Phosphate 14-25 dipeptidyl peptidase 4 Homo sapiens 52-74 24493030-4 2014 Single dose of GLP-1 and the dipeptidyl-peptidase-IV (DPP-IV) inhibitor, sitagliptin, may improve left ventricular function, predominantly in ischemic segments, and attenuate post-ischemic stunning. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 29-52 24493030-4 2014 Single dose of GLP-1 and the dipeptidyl-peptidase-IV (DPP-IV) inhibitor, sitagliptin, may improve left ventricular function, predominantly in ischemic segments, and attenuate post-ischemic stunning. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 54-60 25288908-1 2014 OBJECTIVE: Liraglutide (glucagon-like peptide-1 [GLP-1] receptor agonist) and sitagliptin (dipeptidyl peptidase-4 inhibitor) are approved in Japan for treating type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 91-113 24969577-3 2014 RESEARCH DESIGN AND METHODS: We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months. Sitagliptin Phosphate 190-201 dipeptidyl peptidase 4 Homo sapiens 156-179 25171159-2 2014 In particular, dipeptidyl peptidase-4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) play an increasing role in the management of T2D. Sitagliptin Phosphate 59-70 dipeptidyl peptidase 4 Homo sapiens 15-37 25090264-4 2014 Sitagliptin is a dipeptidyl peptidase-4 inhibitor and a new class of hypoglycemic agents. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 24447683-0 2014 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 27-49 24584549-0 2014 Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 25318234-0 2014 [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Sitagliptin Phosphate 41-52 dipeptidyl peptidase 4 Homo sapiens 1-22 25318234-0 2014 [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Sitagliptin Phosphate 41-52 dipeptidyl peptidase 4 Homo sapiens 24-29 24845072-0 2014 The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 4-9 24584549-1 2014 The dipeptidyl peptidase-4 inhibitor sitagliptin, an antidiabetic agent, which lowers blood glucose levels, also reduces postprandial lipid excursion after a mixed meal. Sitagliptin Phosphate 37-48 dipeptidyl peptidase 4 Homo sapiens 4-26 24916090-9 2014 INTERVENTIONS: Any DPP-4 inhibitor (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin). Sitagliptin Phosphate 36-47 dipeptidyl peptidase 4 Homo sapiens 19-24 24320733-0 2014 The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 4-26 24676549-0 2014 Management of a prediabetes case with the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 58-69 dipeptidyl peptidase 4 Homo sapiens 42-47 24676549-4 2014 The purpose of this article is to report the results of a case in which a patient with prediabetes was treated with the DPP-4 inhibitor, sitagliptin. Sitagliptin Phosphate 137-148 dipeptidyl peptidase 4 Homo sapiens 120-125 24611684-4 2014 Currently different chemical classes of DPP4 inhibitors are in last-stage of clinical trials and few of them such as sitagliptin, vildagliptin, saxagliptin alogliptin and linagliptin have already been successfully released into market. Sitagliptin Phosphate 117-128 dipeptidyl peptidase 4 Homo sapiens 40-44 25003075-1 2014 BACKGROUND: We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus. Sitagliptin Phosphate 87-98 dipeptidyl peptidase 4 Homo sapiens 68-73 24559582-0 2014 Cotreatment with the alpha-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 62-67 24515526-1 2014 DPP-4 inhibitors (sitagliptin, saxagliptin, and linagliptin) are approved for the treatment of diabetes. Sitagliptin Phosphate 18-29 dipeptidyl peptidase 4 Homo sapiens 0-5 24432999-0 2014 Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. Sitagliptin Phosphate 33-44 dipeptidyl peptidase 4 Homo sapiens 0-22 24884787-1 2014 BACKGROUND: The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 70-81 dipeptidyl peptidase 4 Homo sapiens 16-39 24884787-1 2014 BACKGROUND: The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 70-81 dipeptidyl peptidase 4 Homo sapiens 41-46 24499291-6 2014 RESULTS: In head-to-head clinical trials, GLP-1RAs provided greater glycaemic control, weight loss and overall treatment satisfaction vs. the DPP-4 inhibitor sitagliptin. Sitagliptin Phosphate 158-169 dipeptidyl peptidase 4 Homo sapiens 142-147 24531198-4 2014 The journey of DPP-4 inhibitors in the market started from the launch of sitagliptin in 2006 to latest drug teneligliptin in 2012. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 15-20 24607023-0 2014 Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE). Sitagliptin Phosphate 187-198 dipeptidyl peptidase 4 Homo sapiens 166-171 24607023-1 2014 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently used to achieve glycemic targets in patients with type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 27-49 24607023-1 2014 BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently used to achieve glycemic targets in patients with type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 51-56 24186866-8 2014 In conclusion, sitagliptin increased intact GLP-1 and GIP through DPP-4 inhibition but reduced total GLP-1 and GIP (feedback inhibition) without affecting the numerical contribution of the incretin effect. Sitagliptin Phosphate 15-26 dipeptidyl peptidase 4 Homo sapiens 66-71 24503784-0 2014 Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 8-30 24503784-3 2014 We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protected against ischemic left ventricular dysfunction during dobutamine stress in patients with type 2 diabetes mellitus and coronary artery disease. Sitagliptin Phosphate 69-80 dipeptidyl peptidase 4 Homo sapiens 32-54 24503784-8 2014 CONCLUSIONS: The addition of dipeptidyl peptidase-4 inhibitor therapy with sitagliptin to the treatment regime of patients with type 2 diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning. Sitagliptin Phosphate 75-86 dipeptidyl peptidase 4 Homo sapiens 29-51 24297090-4 2014 In this study, we hypothesized that concomitant administration of the dipeptidyl peptidase-4 inhibitor sitagliptin and prednisolone in men at high risk to develop type 2 diabetes could protect against the GC-induced diabetogenic effects. Sitagliptin Phosphate 103-114 dipeptidyl peptidase 4 Homo sapiens 70-92 24407560-1 2014 Sitagliptin (Januvia( ), Xelevia , Glactiv( ), Tesavel( )) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 127-149 24407560-1 2014 Sitagliptin (Januvia( ), Xelevia , Glactiv( ), Tesavel( )) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 151-156 24407560-1 2014 Sitagliptin (Januvia( ), Xelevia , Glactiv( ), Tesavel( )) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Sitagliptin Phosphate 13-20 dipeptidyl peptidase 4 Homo sapiens 127-149 24407560-1 2014 Sitagliptin (Januvia( ), Xelevia , Glactiv( ), Tesavel( )) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Sitagliptin Phosphate 13-20 dipeptidyl peptidase 4 Homo sapiens 151-156 24142388-0 2014 Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation. Sitagliptin Phosphate 14-25 dipeptidyl peptidase 4 Homo sapiens 36-58 24142388-2 2014 A recent clinical trial using sitagliptin, a DPP4 inhibitor approved for type 2 diabetes mellitus, has been shown to be a promising approach in adults with haematological malignancies after umbilical cord blood (UCB) haematopoietic cell transplantation (HCT). Sitagliptin Phosphate 30-41 dipeptidyl peptidase 4 Homo sapiens 45-49 24142388-8 2014 The relationship between sitagliptin concentrations and DPP4 activity was best described by an indirect response model with a negative feedback loop. Sitagliptin Phosphate 25-36 dipeptidyl peptidase 4 Homo sapiens 56-60 24142388-9 2014 Simulations showed that twice daily or three times daily dosage schedules were superior to a once daily schedule for maximal DPP4 inhibition at the lowest sitagliptin exposure. Sitagliptin Phosphate 155-166 dipeptidyl peptidase 4 Homo sapiens 125-129 24580063-1 2014 BACKGROUND: The dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin, saxagliptin, and linagliptin are approved by the US Food and Drug Administration in the treatment of type-2 diabetes. Sitagliptin Phosphate 58-69 dipeptidyl peptidase 4 Homo sapiens 16-38 24580063-1 2014 BACKGROUND: The dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin, saxagliptin, and linagliptin are approved by the US Food and Drug Administration in the treatment of type-2 diabetes. Sitagliptin Phosphate 58-69 dipeptidyl peptidase 4 Homo sapiens 40-45 24020750-0 2014 All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 67-73 25756669-0 2014 More effective DPP4 inhibitors as antidiabetics based on sitagliptin applied QSAR and clinical methods. Sitagliptin Phosphate 57-68 dipeptidyl peptidase 4 Homo sapiens 15-19 24993124-3 2014 Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 20-25 25756669-2 2014 Here, we aim to better understand the molecular features affecting activity of xanthine-based DPP4 inhibitors such as sitagliptin and related compounds and use these features to de novo predict improved sitagliptin derivatives. Sitagliptin Phosphate 118-129 dipeptidyl peptidase 4 Homo sapiens 94-98 25756669-2 2014 Here, we aim to better understand the molecular features affecting activity of xanthine-based DPP4 inhibitors such as sitagliptin and related compounds and use these features to de novo predict improved sitagliptin derivatives. Sitagliptin Phosphate 203-214 dipeptidyl peptidase 4 Homo sapiens 94-98 25756669-8 2014 Based on the established QSAR equations, we propose and analyse 19 new sitagliptin derivatives with possibly improved pharmacological effect as DPP4 inhibitors. Sitagliptin Phosphate 71-82 dipeptidyl peptidase 4 Homo sapiens 144-148 24802729-3 2014 The aim was to assess lymphocyte subpopulations initially and after 14 days of treatment with DPP-4 inhibitors sitagliptin, saxagliptin and vildagliptin. Sitagliptin Phosphate 111-122 dipeptidyl peptidase 4 Homo sapiens 94-99 24623020-5 2014 Among antidiabetic drugs newly approved for marketing between 2003 and 2012, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin had the largest share with 10.5 million prescriptions in 2012. Sitagliptin Phosphate 122-133 dipeptidyl peptidase 4 Homo sapiens 81-103 24623020-5 2014 Among antidiabetic drugs newly approved for marketing between 2003 and 2012, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin had the largest share with 10.5 million prescriptions in 2012. Sitagliptin Phosphate 122-133 dipeptidyl peptidase 4 Homo sapiens 105-110 24817885-4 2014 Sitagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has a low incidence of hypoglycemia, is weight neutral, and, in a small study, did not affect immunosuppressant levels. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 24817885-4 2014 Sitagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has a low incidence of hypoglycemia, is weight neutral, and, in a small study, did not affect immunosuppressant levels. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 39-44 24268212-1 2013 Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 21-43 24739602-1 2014 OBJECTIVE: The aim of this study was to compare the utility of hemoglobin A1c (HbA1c) and glycated albumin (GA) for evaluating the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, in patients with type 2 diabetes. Sitagliptin Phosphate 189-200 dipeptidyl peptidase 4 Homo sapiens 171-176 24163113-0 2013 Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Sitagliptin Phosphate 93-104 dipeptidyl peptidase 4 Homo sapiens 0-22 24163113-1 2013 INTRODUCTION: Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Sitagliptin Phosphate 27-38 dipeptidyl peptidase 4 Homo sapiens 61-83 24163113-1 2013 INTRODUCTION: Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Sitagliptin Phosphate 27-38 dipeptidyl peptidase 4 Homo sapiens 85-90 24163113-21 2013 CONCLUSION: Once daily treatment with sitagliptin provided trough DPP-4 inhibition significantly greater than saxagliptin or vildagliptin administered once daily, and similar to that provided by vildagliptin administered twice daily. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 66-71 24285927-7 2013 When choosing between EQW and a dipeptidyl peptidase-4 (DPP-4) inhibitor, such as sitagliptin, clinicians and patients should consider the differences between the two medications in terms of glucose control (EQW superior to DPP-4 inhibitors), weight control (EQW superior to DPP-4 inhibitors), gastrointestinal tolerability during treatment initiation (EQW inferior to DPP-4 inhibitors), and mode of administration (once-weekly subcutaneous administration versus once-daily oral administration). Sitagliptin Phosphate 82-93 dipeptidyl peptidase 4 Homo sapiens 56-61 23489256-1 2013 AIM: The aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with non-alcoholic fatty liver disease (NAFLD). Sitagliptin Phosphate 115-126 dipeptidyl peptidase 4 Homo sapiens 81-103 24298724-1 2013 Sitagliptin (Januvia) was the first selective inhibitor of dipeptidyl peptidase-4 commercialized for the management of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 59-81 23711188-1 2013 Sitagliptin, a dipeptidyl-peptidase 4 (DPP-4) inhibitor, improves blood glucose control in patients with type 2 diabetes by blocking cleavage of glucagon-like peptide 1 (GLP-1). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 23711188-1 2013 Sitagliptin, a dipeptidyl-peptidase 4 (DPP-4) inhibitor, improves blood glucose control in patients with type 2 diabetes by blocking cleavage of glucagon-like peptide 1 (GLP-1). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 39-44 23711188-7 2013 Individuals taking sitagliptin displayed increases in the percentage of cells expressing higher levels of CD26 at early time-points compared to placebo controls, but these differences resolved by day 28 of treatment. Sitagliptin Phosphate 19-30 dipeptidyl peptidase 4 Homo sapiens 106-110 24772702-0 2013 Clinical review of sitagliptin: a DPP-4 inhibitor. Sitagliptin Phosphate 19-30 dipeptidyl peptidase 4 Homo sapiens 34-39 23707531-5 2013 Five different DPP-4 inhibitors, often called as "gliptins", namely sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin have been approved hitherto for clinical use. Sitagliptin Phosphate 68-79 dipeptidyl peptidase 4 Homo sapiens 15-20 24068868-5 2013 The five available DPP-4 inhibitors, also known as "gliptins" (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. Sitagliptin Phosphate 63-74 dipeptidyl peptidase 4 Homo sapiens 19-24 24031162-2 2013 Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor acts through the incretin pathway and has a glucose dependent mode of action. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 24031162-2 2013 Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor acts through the incretin pathway and has a glucose dependent mode of action. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 39-44 23579178-0 2013 Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 34-56 24772702-4 2013 Sitagliptin is highly selective DPP-4 inhibitor that has been approved for type 2 diabetes therapy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 32-37 23270493-3 2013 We evaluated the feasibility of systemic DPP-4 inhibition using sitagliptin to enhance engraftment of single-unit UCB grafts in adults with hematological malignancies. Sitagliptin Phosphate 64-75 dipeptidyl peptidase 4 Homo sapiens 41-46 24039399-1 2013 Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-46 23488656-3 2013 Dipeptidyl peptidase-4 (DPP-4) inhibitors, vildagliptin and sitagliptin, are oral anti-diabetic drugs often prescribed in patients with cardiovascular disease. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 0-22 23488656-3 2013 Dipeptidyl peptidase-4 (DPP-4) inhibitors, vildagliptin and sitagliptin, are oral anti-diabetic drugs often prescribed in patients with cardiovascular disease. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 24-29 23621381-3 2013 AREAS COVERED: An extensive literature search was performed to analyze clinical cases of acute pancreatitis reported in the literature or to the Food and Drug Administration (FDA), in randomized clinical trials, and in observational studies with five DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. Sitagliptin Phosphate 269-280 dipeptidyl peptidase 4 Homo sapiens 251-256 23805228-6 2013 On the other hand, the selective DPPIV inhibitor sitagliptin inhibited the increase in TNF-alpha mRNA and protein expression as well as the increase in ERK, c-Fos, NF-kappaB p50, NF-kappaB p65, and CUX1 levels. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 33-38 23671547-1 2013 BACKGROUND: Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect being demonstrated both when it is administered alone or in combination with other oral antidiabetic agents. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 75-97 23440284-2 2013 Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)-based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis. Sitagliptin Phosphate 176-197 dipeptidyl peptidase 4 Homo sapiens 142-164 24843649-1 2013 AIMS/INTRODUCTION: The efficacy and safety of sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, when added to metformin monotherapy was examined in Japanese patients with type 2 diabetes. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 78-100 23700263-1 2013 BACKGROUND: Sitagliptin, the first of a new class of dipeptidyl peptidase-4 (DPP-4)-inhibitory oral antihyperglycaemic drugs (OHDs), was introduced in Japan in December 2009. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 53-75 23700263-1 2013 BACKGROUND: Sitagliptin, the first of a new class of dipeptidyl peptidase-4 (DPP-4)-inhibitory oral antihyperglycaemic drugs (OHDs), was introduced in Japan in December 2009. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 77-82 23667754-2 2013 The aim of this study was to determine whether single pre-prandial sitagliptin, the DPP-IV inhibitor, administration might have an effect on the rate of liquid gastric emptying using the (13)C-acetic acid breath test. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 84-90 23270493-9 2013 Optimizing sitagliptin dosing to achieve more sustained DPP-4 inhibition may further improve outcome. Sitagliptin Phosphate 11-22 dipeptidyl peptidase 4 Homo sapiens 56-61 23116881-1 2013 AIMS: To assess efficacy and safety of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in combination therapy with metformin (>=1500 mg/day) and pioglitazone (>=30 mg/day) in patients with type 2 diabetes (T2DM) with inadequate glycemic control (hemoglobin A1c [HbA1c] >=7.5% and <=11%). Sitagliptin Phosphate 39-50 dipeptidyl peptidase 4 Homo sapiens 54-76 23468467-2 2013 Comparison of two oral dipeptidyl peptidase (DPP)-4 inhibitors, sitagliptin and linagliptin, for type 2 diabetes mellitus (T2DM) treatment was used as an example. Sitagliptin Phosphate 64-75 dipeptidyl peptidase 4 Homo sapiens 23-51 23129260-1 2012 A generalized skin eruption with strong itching was induced by sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in a patient almost 6 months after initiation of the drug. Sitagliptin Phosphate 63-74 dipeptidyl peptidase 4 Homo sapiens 78-100 23432786-5 2013 The participants received 50 to 100 mg of the DPP-4 inhibitor sitagliptin once daily for 12 months. Sitagliptin Phosphate 62-73 dipeptidyl peptidase 4 Homo sapiens 46-51 23261963-3 2013 High GLP-2 concentrations resulted from iv bolus injections, whereas a more protracted stimulation was obtained by subcutaneous injections and the addition of an inhibitor of GLP-2 degradation, a DPP-4 inhibitor, sitagliptin. Sitagliptin Phosphate 213-224 dipeptidyl peptidase 4 Homo sapiens 196-201 23386232-0 2013 Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Sitagliptin Phosphate 34-45 dipeptidyl peptidase 4 Homo sapiens 0-22 23386232-2 2013 We hypothesized that sitagliptin, a DPP4-inhibitor, could improve endothelial dysfunction in DM patients with coronary artery disease (CAD). Sitagliptin Phosphate 21-32 dipeptidyl peptidase 4 Homo sapiens 36-40 23386390-0 2013 Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Sitagliptin Phosphate 40-51 dipeptidyl peptidase 4 Homo sapiens 24-29 23536954-1 2013 The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class. Sitagliptin Phosphate 153-164 dipeptidyl peptidase 4 Homo sapiens 54-76 22519906-12 2012 The risk of hypoglycaemia was low with DPP-4 inhibitor treatment (RR 0.92 [0.74, 1.15] compared to placebo, RR 0.20 [0.17, 0.24] compared to sulphonylureas) in the absence of sulphonylurea or insulin co-therapy, but significantly elevated for combination therapy of sulphonylurea or insulin with sitagliptin or linagliptin (RR 1.86 [1.46, 2.37] compared to placebo). Sitagliptin Phosphate 296-307 dipeptidyl peptidase 4 Homo sapiens 39-44 23062489-0 2013 A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Sitagliptin Phosphate 36-47 dipeptidyl peptidase 4 Homo sapiens 2-24 23062489-2 2013 Here, we examined the effect of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, on systemic inflammation and pro-inflammatory (M1)/anti-inflammatory (M2)-like phenotypes of peripheral blood monocytes in diabetic patients. Sitagliptin Phosphate 32-43 dipeptidyl peptidase 4 Homo sapiens 47-69 23062489-2 2013 Here, we examined the effect of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, on systemic inflammation and pro-inflammatory (M1)/anti-inflammatory (M2)-like phenotypes of peripheral blood monocytes in diabetic patients. Sitagliptin Phosphate 32-43 dipeptidyl peptidase 4 Homo sapiens 71-76 23062489-11 2013 CONCLUSIONS/INTERPRETATION: This study is the first to show that a DPP-4 inhibitor, sitagliptin, reduces inflammatory cytokines and improves the unfavorable M1/M2-like phenotypes of peripheral blood monocytes in Japanese type 2 diabetic patients. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 67-72 23187735-3 2013 In this report we demonstrate that treatment of human vascular endothelial cells with the DPP-IV inhibitor sitagliptin inhibited tumour necrosis factor alpha (TNFalpha) induction of plasminogen activator inhibitor type-1 (PAI-1), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA and protein expression and that this effect was observed to be both GLP-1-dependent and independent. Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 90-96 23186950-2 2013 This study evaluated the effects of sitagliptin (dipeptidyl peptidase-IV [DPP-IV] inhibitor, approved for patients with type 2 diabetes), in adults with type 1 diabetes to improve glycemic control through decreasing postprandial glucagon. Sitagliptin Phosphate 36-47 dipeptidyl peptidase 4 Homo sapiens 49-72 23186950-2 2013 This study evaluated the effects of sitagliptin (dipeptidyl peptidase-IV [DPP-IV] inhibitor, approved for patients with type 2 diabetes), in adults with type 1 diabetes to improve glycemic control through decreasing postprandial glucagon. Sitagliptin Phosphate 36-47 dipeptidyl peptidase 4 Homo sapiens 74-80 24601174-4 2013 The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. Sitagliptin Phosphate 113-124 dipeptidyl peptidase 4 Homo sapiens 96-101 23129260-1 2012 A generalized skin eruption with strong itching was induced by sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in a patient almost 6 months after initiation of the drug. Sitagliptin Phosphate 63-74 dipeptidyl peptidase 4 Homo sapiens 102-107 22982114-10 2012 CD26 inhibition with sitagliptin - a drug currently used in diabetic patients - resulted in improved in vitro migration capacities of MNCs. Sitagliptin Phosphate 21-32 dipeptidyl peptidase 4 Homo sapiens 0-4 22941471-1 2012 BACKGROUND: Sitagliptin, the first of a new class of dipeptidyl peptidase-4 (DPP-4)-inhibitory oral antihyperglycemic drugs (OHDs), was introduced in Japan in December 2009. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 53-75 22941471-1 2012 BACKGROUND: Sitagliptin, the first of a new class of dipeptidyl peptidase-4 (DPP-4)-inhibitory oral antihyperglycemic drugs (OHDs), was introduced in Japan in December 2009. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 77-82 22982114-12 2012 Treating patients shortly post MI with sitagliptin to inhibit CD26 may therefore increase MNC homing to the infarct area and could improve cardiac recovery and repair. Sitagliptin Phosphate 39-50 dipeptidyl peptidase 4 Homo sapiens 62-66 23166419-0 2012 The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. Sitagliptin Phosphate 37-48 dipeptidyl peptidase 4 Homo sapiens 4-26 22745245-1 2012 CONTEXT: Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades the incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, and thus, sitagliptin increases their bioavailability. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 51-74 22688551-1 2012 OBJECTIVE: Evaluate the effects of two dipeptidyl peptidase-IV (DPP-4) inhibitors, sitagliptin and vildagliptin, known to have different efficacy on mean amplitude of glycemic excursions (MAGE), on oxidative stress, and on systemic inflammatory markers in patients with type 2 diabetes. Sitagliptin Phosphate 83-94 dipeptidyl peptidase 4 Homo sapiens 64-69 23110260-3 2012 The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. Sitagliptin Phosphate 77-88 dipeptidyl peptidase 4 Homo sapiens 4-10 23110260-3 2012 The DPP IV inhibitors saxagliptin, vildagliptin, linagliptin, alogliptin and sitagliptin function by inhibiting the enzyme DPP IV, which breaks down GLP-1 and GIP, and have had significant success. Sitagliptin Phosphate 77-88 dipeptidyl peptidase 4 Homo sapiens 123-129 23024732-1 2012 BACKGROUND: Sitagliptin is a DPP-4 inhibitor that became available for use in Japan three years ago. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 29-34 23040117-3 2012 The purpose of this mechanistic study was to evaluate the effects of treatment with the dipeptidyl peptidase (DPP) 4 inhibitor sitagliptin on myocardial glucose uptake in patients with nonischemic cardiomyopathy. Sitagliptin Phosphate 127-138 dipeptidyl peptidase 4 Homo sapiens 88-116 23040117-8 2012 CONCLUSIONS: Therapy with the DPP-4 inhibitor sitagliptin results in increased myocardial glucose uptake in nondiabetic patients with nonischemic cardiomyopathy. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 30-35 22519909-0 2012 Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Sitagliptin Phosphate 61-72 dipeptidyl peptidase 4 Homo sapiens 26-49 22519909-2 2012 The dipeptidyl peptidase-IV inhibitor sitagliptin and the angiotensin II type 1 receptor (AT(1) receptor) blocker losartan have a common target action in the pancreata. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 4-27 22745245-1 2012 CONTEXT: Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades the incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, and thus, sitagliptin increases their bioavailability. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 76-82 22745245-1 2012 CONTEXT: Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades the incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, and thus, sitagliptin increases their bioavailability. Sitagliptin Phosphate 199-210 dipeptidyl peptidase 4 Homo sapiens 51-74 22745245-1 2012 CONTEXT: Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-IV (DPP-IV), which degrades the incretins, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, and thus, sitagliptin increases their bioavailability. Sitagliptin Phosphate 199-210 dipeptidyl peptidase 4 Homo sapiens 76-82 22745245-3 2012 Because DPP-IV is expressed as CD26 on cell membranes and because CD26 mediates proinflammatory signals, we hypothesized that sitagliptin may exert an antiinflammatory effect. Sitagliptin Phosphate 126-137 dipeptidyl peptidase 4 Homo sapiens 8-14 22745245-3 2012 Because DPP-IV is expressed as CD26 on cell membranes and because CD26 mediates proinflammatory signals, we hypothesized that sitagliptin may exert an antiinflammatory effect. Sitagliptin Phosphate 126-137 dipeptidyl peptidase 4 Homo sapiens 66-70 22745245-7 2012 Fasting glucagon-like peptide-1 concentrations increased significantly, whereas the mRNA expression in mononuclear cell of CD26, the proinflammatory cytokine, TNFalpha, the receptor for endotoxin, Toll-like receptor (TLR)-4, TLR-2, and proinflammatory kinases, c-Jun N-terminal kinase-1 and inhibitory-kappaB kinase (IKKbeta), and that of the chemokine receptor CCR-2 fell significantly after 12 wk of sitagliptin. Sitagliptin Phosphate 402-413 dipeptidyl peptidase 4 Homo sapiens 123-127 22745245-8 2012 TLR-2, IKKbeta, CCR-2, and CD26 expression and nuclear factor-kappaB binding also fell after a single dose of sitagliptin. Sitagliptin Phosphate 110-121 dipeptidyl peptidase 4 Homo sapiens 27-31 22745245-11 2012 The suppression of CD26 expression suggests that sitagliptin may inhibit the synthesis of DPP-IV in addition to inhibiting its action. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 19-23 22745245-11 2012 The suppression of CD26 expression suggests that sitagliptin may inhibit the synthesis of DPP-IV in addition to inhibiting its action. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 90-96 22648661-1 2012 AIMS/HYPOTHESIS: Inhibitors of dipeptidyl peptidase-IV (DPP-IV), such as sitagliptin, increase glucagon-like peptide-1 (GLP-1) concentrations and are current treatment options for patients with type 2 diabetes mellitus. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 31-54 22648661-1 2012 AIMS/HYPOTHESIS: Inhibitors of dipeptidyl peptidase-IV (DPP-IV), such as sitagliptin, increase glucagon-like peptide-1 (GLP-1) concentrations and are current treatment options for patients with type 2 diabetes mellitus. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 56-62 21981936-0 2012 Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. Sitagliptin Phosphate 24-35 dipeptidyl peptidase 4 Homo sapiens 39-62 22870172-1 2012 BACKGROUND: Sitagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the inactivation of incretins, increasing the endogenous active incretin levels. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 38-60 22870172-1 2012 BACKGROUND: Sitagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the inactivation of incretins, increasing the endogenous active incretin levels. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 62-67 22297059-1 2012 OBJECTIVE: To describe a case illustrating the use of sitagliptin, an inhibitor of dipeptidyl-peptidase-4 (DPP-4), in anti-glutamic acid decarboxylase antibody-positive diabetes mellitus in association with a rare ataxic variant of stiff person syndrome. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 83-105 22555471-8 2012 GLP-1 agonists (exenatide and liraglutide) and DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin and linagliptin) currently represent effective treatment options for patients with type 2 diabetes. Sitagliptin Phosphate 65-76 dipeptidyl peptidase 4 Homo sapiens 47-52 22297059-1 2012 OBJECTIVE: To describe a case illustrating the use of sitagliptin, an inhibitor of dipeptidyl-peptidase-4 (DPP-4), in anti-glutamic acid decarboxylase antibody-positive diabetes mellitus in association with a rare ataxic variant of stiff person syndrome. Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 107-112 22297059-2 2012 METHODS: We present our experience with use of the DPP-4 inhibitor sitagliptin for management of autoimmune diabetes in a elderly woman and highlight the association of diabetes with other autoimmune conditions. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 51-56 22683131-2 2012 We aimed to compare the efficacy, tolerability, and safety of insulin glargine and sitagliptin, a DPP-4 inhibitor, in patients whose disease was uncontrolled with metformin. Sitagliptin Phosphate 83-94 dipeptidyl peptidase 4 Homo sapiens 98-103 21928236-3 2012 Sitagliptin is a dipeptidyl-peptidase IV inhibitor with dose adjustments based on eCLCr. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-40 22644981-13 2012 CONCLUSION: In a patient with type 2 diabetes mellitus, the addition of the incretin mimetic exenatide and the dipeptidyl peptidase-4 inhibitor sitagliptin to glipizide therapy appeared effective and safe. Sitagliptin Phosphate 144-155 dipeptidyl peptidase 4 Homo sapiens 111-133 22475049-4 2012 In comparison, both vildagliptin (3.5 minutes) and sitagliptin ( < 2 minutes) rapidly dissociated from DPP4 at 37 C. Saxagliptin and 5-hydroxysaxagliptin are selective for inhibition of DPP4 versus other DPP family members and a large panel of other proteases, and have similar potency and efficacy across multiple species.Inhibition of plasma DPP activity is used as a biomarker in animal models and clinical trials. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 189-193 21898126-2 2012 Miglitol and dipeptidyl peptidase-4 inhibitors, such as sitagliptin, enhance plasma active GLP-1 concentrations via different mechanisms; therefore, combined therapy with these agents was more effective than monotherapy. Sitagliptin Phosphate 56-67 dipeptidyl peptidase 4 Homo sapiens 13-35 23946679-3 2012 In the present report, we investigated the effect of addition of sitagliptin, the first-in-class DPP-4 inhibitor, to ongoing metformin and sulfonylurea therapy in three female Japanese patients with T2DM who refused insulin therapy. Sitagliptin Phosphate 65-76 dipeptidyl peptidase 4 Homo sapiens 97-102 24843562-2 2012 In this study, we attempted to estimate HbA1c using the change in GA level before and after the first 2 weeks (DeltaGA2w) of administration of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Sitagliptin Phosphate 143-154 dipeptidyl peptidase 4 Homo sapiens 158-180 22398230-1 2012 Photosensitivity to sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is reported. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 35-57 22398230-1 2012 Photosensitivity to sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is reported. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 59-64 21899912-0 2012 Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 48-70 22309337-3 2012 We report a psoriasiform eruption induced by sitagliptin, a DPP-IV inhibitor. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 60-66 22186413-0 2012 Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Sitagliptin Phosphate 65-76 dipeptidyl peptidase 4 Homo sapiens 31-53 22186413-10 2012 These studies demonstrate, for the first time, that sitagliptin exerts direct, DPP-IV-independent effects on intestinal L cells, activating cAMP and ERK1/2 signaling and stimulating total GLP-1 secretion. Sitagliptin Phosphate 52-63 dipeptidyl peptidase 4 Homo sapiens 79-85 22186413-2 2012 The dipeptidylpeptidase-IV (DPP-IV) inhibitor, sitagliptin, prevents GLP-1 degradation and is used in the clinic to treat patients with type 2 diabetes mellitus, leading to improved glycated hemoglobin levels. Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 4-26 22186413-2 2012 The dipeptidylpeptidase-IV (DPP-IV) inhibitor, sitagliptin, prevents GLP-1 degradation and is used in the clinic to treat patients with type 2 diabetes mellitus, leading to improved glycated hemoglobin levels. Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 28-34 23077137-1 2012 BACKGROUND: Treatment with the combination of sitagliptin (a dipeptidyl peptidase 4 inhibitor which improves glycemic control) and simvastatin (a well characterized lipid-lowering agent) may be considered an appropriate approach to management of type 2 diabetes and its associated increased risk of cardiovascular disease. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 61-83 22120969-10 2012 GLP-1R antagonist exendin(9-39) or DPP-4 inhibitor sitagliptin, which abolished GLP-1(9-36) formation, at the concentration of 5000 pmol/L partially blocked the effects of GLP-1 on eNOS. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 35-40 22056790-0 2012 Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-38 22056790-2 2012 After sitagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, was administered for control of blood glucose, psoriatic skin lesions were gradually diminished, although HbA1c did not improve. Sitagliptin Phosphate 6-17 dipeptidyl peptidase 4 Homo sapiens 21-44 22056790-2 2012 After sitagliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor, was administered for control of blood glucose, psoriatic skin lesions were gradually diminished, although HbA1c did not improve. Sitagliptin Phosphate 6-17 dipeptidyl peptidase 4 Homo sapiens 46-52 22277726-4 2012 We encountered an 86-year-old woman with type 2 diabetes and depression, who was transferred to the emergency room 4h after ingestion of 1,700 mg of the DPP-4 inhibitor sitagliptin (1,700 mg is 17 times greater than the approved maximum dose). Sitagliptin Phosphate 169-180 dipeptidyl peptidase 4 Homo sapiens 153-158 22621443-2 2012 This study, approved by the institutional review board of Hanzoumon Diabetes City Atlas Clinic, examined whether DPP-4 inhibitor sitagliptin could safely achieve good glycemic control without severe hypoglycemia by employing the "added food" concept. Sitagliptin Phosphate 129-140 dipeptidyl peptidase 4 Homo sapiens 113-118 22864134-0 2012 Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 13-18 22864134-2 2012 We report a 48-year-old woman with type 2 diabetes who was diagnosed with rheumatoid arthritis (RA) after continued polyarthritis and an increase in rheumatoid factor up to 86 IU/mL after three months of treatment with sitagliptin, a DPP-4 inhibitor. Sitagliptin Phosphate 219-230 dipeptidyl peptidase 4 Homo sapiens 234-239 23125920-5 2012 DPP-4 inhibitors such as sitagliptin and linagliptin prevent the inactivation of endogenous GLP-1 and GIP through competitive inhibition of the DPP-4 enzyme. Sitagliptin Phosphate 25-36 dipeptidyl peptidase 4 Homo sapiens 0-5 23125920-5 2012 DPP-4 inhibitors such as sitagliptin and linagliptin prevent the inactivation of endogenous GLP-1 and GIP through competitive inhibition of the DPP-4 enzyme. Sitagliptin Phosphate 25-36 dipeptidyl peptidase 4 Homo sapiens 144-149 22153807-2 2012 We investigated the relationship between the baseline serum level of soluble CD 26/DPP-4 and the response to treatment with sitagliptin, a DPP-4 inhibitor, over 24 weeks in patients who had type 2 diabetes inadequately controlled by metformin and/or sulfonylurea therapy. Sitagliptin Phosphate 124-135 dipeptidyl peptidase 4 Homo sapiens 77-82 22950787-1 2012 Sitagliptin, a selective dipeptidyl peptidase-4 inhibitor drug is used to treat type-2 diabetes (T2DM). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-47 22153807-0 2012 Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 23-50 22153807-0 2012 Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 52-57 22153807-0 2012 Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 99-104 22153807-2 2012 We investigated the relationship between the baseline serum level of soluble CD 26/DPP-4 and the response to treatment with sitagliptin, a DPP-4 inhibitor, over 24 weeks in patients who had type 2 diabetes inadequately controlled by metformin and/or sulfonylurea therapy. Sitagliptin Phosphate 124-135 dipeptidyl peptidase 4 Homo sapiens 83-88 22153807-2 2012 We investigated the relationship between the baseline serum level of soluble CD 26/DPP-4 and the response to treatment with sitagliptin, a DPP-4 inhibitor, over 24 weeks in patients who had type 2 diabetes inadequately controlled by metformin and/or sulfonylurea therapy. Sitagliptin Phosphate 124-135 dipeptidyl peptidase 4 Homo sapiens 139-144 22439134-1 2011 In the context of a need for improved strategies to control glycemia in patients with type 2 diabetes, new information was discussed during the American Diabetes Association"s annual meeting on the dipeptidyl peptidase 4 inhibitor sitagliptin. Sitagliptin Phosphate 231-242 dipeptidyl peptidase 4 Homo sapiens 198-220 22189184-12 2011 CONCLUSIONS: In conclusion, CGM measurements revealed that a combination of the alpha-GI miglitol and the DPP-4 inhibitor sitagliptin effectively reduced postprandial glucose fluctuation and stabilized blood glucose levels. Sitagliptin Phosphate 122-133 dipeptidyl peptidase 4 Homo sapiens 106-111 21892746-6 2011 GLP-1 analogs and sitagliptin, an oral dipeptidyl peptidase IV inhibitor, limit myocardial infarct size in animal models by increasing intracellular cAMP levels and activating protein kinase A, whereas metformin protects the heart by activating AMP-activated protein kinase. Sitagliptin Phosphate 18-29 dipeptidyl peptidase 4 Homo sapiens 39-62 21209231-1 2011 Sitagliptin is a dipeptidyl peptidase-IV (DPP-4) inhibitor used for the treatment of patients with type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-40 21932180-1 2011 Sitagliptin is a stable inhibitor of dipeptidyl peptidase-IV, a responsible enzyme that mainly inactivates glucagon-like peptide-1 (GLP-1), and now one of the widely used agents for the treatment of diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 37-60 21209231-1 2011 Sitagliptin is a dipeptidyl peptidase-IV (DPP-4) inhibitor used for the treatment of patients with type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 42-47 21636156-3 2011 He began receiving DPP-IV inhibitor (Sitagliptin 50 mg, daily), in lieu of insulin injection. Sitagliptin Phosphate 37-48 dipeptidyl peptidase 4 Homo sapiens 19-25 21913883-1 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. Sitagliptin Phosphate 59-70 dipeptidyl peptidase 4 Homo sapiens 4-26 21913883-1 2011 The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. Sitagliptin Phosphate 59-70 dipeptidyl peptidase 4 Homo sapiens 28-33 21812507-2 2011 The "first-in-class" DPP-4 inhibitor, sitagliptin, was approved in 2006; it was followed by vildagliptin (available in the EU and many other countries since 2007, although approval in the US is still pending), saxagliptin (in 2009), alogliptin (in 2010, presently only in Japan) and linagliptin, which was approved in the US in May 2011 and is undergoing regulatory review in Japan and the EU. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 21-26 21382532-2 2011 In this study, the effect of aqueous extract of sitagliptin, a selective dipeptidylpeptidase-4 inhibitor, on the mast cell-mediated allergic response was studied with the possible mechanisms of action, focusing on the histamine release and pro-inflammatory cytokine secretion in mast cells. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 73-94 21727749-4 2011 The incritin memetics are potentially safe during Ramadan; the DPP4 inhibitors vildagliptin and sitagliptin provide an effective and safe therapeutic option, administered either alone or in combination with metformin or sulfonylureas. Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 63-67 21651449-4 2011 This review is intended to provide a comprehensive overview of the DPP-IV inhibitor sitagliptin, its clinical use and an expert opinion about its place in the treatment algorithm of diabetes management. Sitagliptin Phosphate 84-95 dipeptidyl peptidase 4 Homo sapiens 67-73 21504334-1 2011 BACKGROUND: This study was performed to examine the efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes using continuous glucose monitoring (CGM) of 24-h glycemic changes. Sitagliptin Phosphate 64-75 dipeptidyl peptidase 4 Homo sapiens 79-101 21334333-3 2011 METHODS: We examined the US Food and Drug Administration"s database of reported adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associated with 4 other medications were compared as controls. Sitagliptin Phosphate 158-169 dipeptidyl peptidase 4 Homo sapiens 125-147 21738898-1 2011 BACKGROUND: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 46-66 21942079-1 2011 Sitagliptin (Januvia), the first selective inhibitor of dipeptidylpeptidase-4 with a so-called incretin effect, has been evaluated in SUGAR, a large Belgian prospective observational study carried out in general practice. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 56-77 21668924-0 2011 Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 14-36 21595272-2 2011 Sitagliptin is one of several DPP-4 inhibitors. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 30-35 21738898-1 2011 BACKGROUND: Sitagliptin is a highly selective dipeptidyl peptide-4 (DPP-4) inhibitor that increases blood levels of active glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrophic polypeptide (GIP), resulting in increased insulin secretion. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 68-73 21194356-8 2011 In situ, DPP activity in ventricular microvasculature was completely inhibited by sitagliptin, indicating that DPPIV is the predominant DPPIV-like enzyme in this organ. Sitagliptin Phosphate 82-93 dipeptidyl peptidase 4 Homo sapiens 111-116 21194356-8 2011 In situ, DPP activity in ventricular microvasculature was completely inhibited by sitagliptin, indicating that DPPIV is the predominant DPPIV-like enzyme in this organ. Sitagliptin Phosphate 82-93 dipeptidyl peptidase 4 Homo sapiens 136-141 21284702-0 2011 Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Sitagliptin Phosphate 105-116 dipeptidyl peptidase 4 Homo sapiens 45-67 21284702-1 2011 AIMS: Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) used to treat type 2 diabetes. Sitagliptin Phosphate 6-17 dipeptidyl peptidase 4 Homo sapiens 46-68 21284702-1 2011 AIMS: Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) used to treat type 2 diabetes. Sitagliptin Phosphate 6-17 dipeptidyl peptidase 4 Homo sapiens 70-75 21284702-10 2011 After correction for dilution and competition effects during assay, doses of sitagliptin >=50mg resulted in weighted average DPP-4 inhibition from 0-24h post-dose >94% (without correction, >78%). Sitagliptin Phosphate 77-88 dipeptidyl peptidase 4 Homo sapiens 128-133 21319871-1 2011 Sitagliptin/metformin is a single-tablet, fixed-dose combination of the dipeptidyl peptidase-4 inhibitor sitagliptin and the biguanide antihyperglycaemic metformin that achieves greater improvements in glycaemic control than either component alone in patients with type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 72-94 21319871-1 2011 Sitagliptin/metformin is a single-tablet, fixed-dose combination of the dipeptidyl peptidase-4 inhibitor sitagliptin and the biguanide antihyperglycaemic metformin that achieves greater improvements in glycaemic control than either component alone in patients with type 2 diabetes mellitus. Sitagliptin Phosphate 105-116 dipeptidyl peptidase 4 Homo sapiens 72-94 21304217-0 2011 Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 21035885-1 2011 We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment. Sitagliptin Phosphate 155-166 dipeptidyl peptidase 4 Homo sapiens 282-286 21488586-2 2011 Sitagliptin and vildagliptin are dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as "gliptins". Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 33-55 21488586-2 2011 Sitagliptin and vildagliptin are dipeptidyl peptidase 4 (DPP-4) inhibitors, also known as "gliptins". Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 57-62 21304217-1 2011 Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a newly developed oral hypoglycemic agent. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 21304217-1 2011 Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a newly developed oral hypoglycemic agent. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 39-44 20051299-2 2010 Thereupon, we initiated a phase III, multi-centre, randomised, placebo-controlled efficacy and safety study (n=100) analyzing the effect of combined application of G-CSF and Sitagliptin, which is a clinically admitted, anti-diabetic DPP-IV-inhibitor, after acute myocardial infarction ("SITAGRAMI-Trial"; EudraCT Number: 2007-003941-34). Sitagliptin Phosphate 174-185 dipeptidyl peptidase 4 Homo sapiens 233-239 21819162-1 2011 BACKGROUND AND OBJECTIVE: Vildagliptin and sitagliptin are oral dipeptidyl peptidase 4 inhibitors approved in Japan for the treatment of type 2 diabetes mellitus when adequate glycaemic control is not achieved with diet, exercise or sulphonylureas. Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 64-86 21966329-9 2011 These DPP-4 inhibitors include sitagliptin, saxagliptin, vildagliptin and many others which are still in the experimental phase. Sitagliptin Phosphate 31-42 dipeptidyl peptidase 4 Homo sapiens 6-11 21293084-7 2011 Sitagliptin and saxagliptin, both approved for use in the United States, modulate incretin physiology by inhibiting degradation of GLP-1 by the enzyme dipeptidyl peptidase-4 (DPP-4). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 151-173 21293084-7 2011 Sitagliptin and saxagliptin, both approved for use in the United States, modulate incretin physiology by inhibiting degradation of GLP-1 by the enzyme dipeptidyl peptidase-4 (DPP-4). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 175-180 20938933-3 2010 Many DPP4 inhibitors, such as sitagliptin and vildagliptin, have been developed and marketed, but superior therapeutic agents are still required. Sitagliptin Phosphate 30-41 dipeptidyl peptidase 4 Homo sapiens 5-9 21189532-4 2010 Janumet is a fixed-dose combination of sitagliptin, a specific inhibitor of dipeptidylpeptidase-4 that blocks the rapid degradation of so-called incretin hormones (resulting in a potentiation of insulin secretion and reduction of glucagon secretion in a glucose-dependent manner), and of metformin, a biguanide compound that reduces glucose hepatic production and slightly improves insulin sensitivity. Sitagliptin Phosphate 39-50 dipeptidyl peptidase 4 Homo sapiens 76-97 20708812-2 2010 Since the launch of sitagliptin in 2006, a compelling body of evidence has accumulated showing that dipeptidyl peptidase-4 (DPP-4) inhibitors, which augment endogenous GLP-1 and GIP levels, represent an important advance in the management of T2DM. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 100-122 20708812-2 2010 Since the launch of sitagliptin in 2006, a compelling body of evidence has accumulated showing that dipeptidyl peptidase-4 (DPP-4) inhibitors, which augment endogenous GLP-1 and GIP levels, represent an important advance in the management of T2DM. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 124-129 20708812-3 2010 Currently, three DPP-4 inhibitors - sitagliptin, vildagliptin and saxagliptin - have been approved in various countries worldwide. Sitagliptin Phosphate 36-47 dipeptidyl peptidase 4 Homo sapiens 17-22 20679179-5 2010 Sitagliptin decreased serum dipeptidyl peptidase-IV activity (13.08+-1.45 versus 30.28+-1.76 nmol/mL/min during placebo; P<=0.001) and fasting blood glucose. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 28-51 20707611-3 2010 DPP IV inhibitors (sitagliptin, vildagliptin, saxagliptin) offer new options for combined pharmacological therapy. Sitagliptin Phosphate 19-30 dipeptidyl peptidase 4 Homo sapiens 0-6 21206627-1 2010 Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 53-76 21205499-7 2010 Three inhibitors of DPP4: sitagliptin, and vildagliptin and saxagliptin produce a prolonged inhibition of DPP4 and as a consequence increased effect of native incretins with better control of fasting and postprandial glucose and improve on A1c with a very few hypoglycemic events. Sitagliptin Phosphate 26-37 dipeptidyl peptidase 4 Homo sapiens 20-24 21205499-7 2010 Three inhibitors of DPP4: sitagliptin, and vildagliptin and saxagliptin produce a prolonged inhibition of DPP4 and as a consequence increased effect of native incretins with better control of fasting and postprandial glucose and improve on A1c with a very few hypoglycemic events. Sitagliptin Phosphate 26-37 dipeptidyl peptidase 4 Homo sapiens 106-110 20590736-1 2010 OBJECTIVE: To compare the efficacy and safety of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and voglibose (an alpha-glucosidase inhibitor) monotherapy in Japanese patients with type 2 diabetes who have inadequate glycaemic control (HbA1c > or =6.5% and <10.0%) on diet and exercise. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 64-86 20629618-3 2010 A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. Sitagliptin Phosphate 106-117 dipeptidyl peptidase 4 Homo sapiens 65-87 20629618-3 2010 A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. Sitagliptin Phosphate 106-117 dipeptidyl peptidase 4 Homo sapiens 89-94 20927248-0 2010 Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 37-60 20927248-1 2010 OBJECTIVE: The aim of this study was to evaluate the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin with respect to mode of inhibition and its in vivo duration of inhibition and efficacy in type 2 diabetes animal model. Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 53-76 20927248-1 2010 OBJECTIVE: The aim of this study was to evaluate the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin with respect to mode of inhibition and its in vivo duration of inhibition and efficacy in type 2 diabetes animal model. Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 78-84 20927248-6 2010 The reversibility of the inhibitor was assessed by a dissociation study of the DPP-IV-sitagliptin complex. Sitagliptin Phosphate 86-97 dipeptidyl peptidase 4 Homo sapiens 79-85 20927248-8 2010 RESULTS: Sitagliptin is a competitive, reversible, fast and tight binding DPP-IV inhibitor. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 74-80 20927248-11 2010 CONCLUSION: The DPP-IV inhibitor sitagliptin behaves as a competitive, tight, and fast binding inhibitor. Sitagliptin Phosphate 33-44 dipeptidyl peptidase 4 Homo sapiens 16-22 20539105-6 2010 Saxagliptin is another dipeptidyl peptidase-4 (after sitagliptin) that is approved for the management of type 2 diabetes. Sitagliptin Phosphate 53-64 dipeptidyl peptidase 4 Homo sapiens 23-45 20357375-0 2010 The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Sitagliptin Phosphate 42-53 dipeptidyl peptidase 4 Homo sapiens 9-31 20357375-2 2010 Because SDF-1alpha is a substrate of dipeptidyl-peptidase-4 (DPP-4), we investigated whether the DPP-4 inhibitor sitagliptin modulates EPC levels in type 2 diabetic patients. Sitagliptin Phosphate 113-124 dipeptidyl peptidase 4 Homo sapiens 97-102 20644202-5 2010 Agents that act as incretin mimetics, such as exenatide and liraglutide, and DPP-4 inhibitors, such as sitagliptin phosphate and saxagliptin, improve glycated hemoglobin levels either as monotherapy or in combination with other agents. Sitagliptin Phosphate 103-124 dipeptidyl peptidase 4 Homo sapiens 77-82 20412332-2 2010 The objective of this review was to describe the controlled preclinical and clinical trial data regarding the incidence of pancreatitis with sitagliptin, the first DPP-4 inhibitor approved for use in patients with T2DM. Sitagliptin Phosphate 141-152 dipeptidyl peptidase 4 Homo sapiens 164-169 20415690-8 2010 RESULTS: DSP-7238 and sitagliptin both competitively inhibited recombinant human DPP IV (rhDPP IV) with K(i) values of 0.60 and 2.1 nM respectively. Sitagliptin Phosphate 22-33 dipeptidyl peptidase 4 Homo sapiens 81-87 21437074-0 2010 Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Sitagliptin Phosphate 53-64 dipeptidyl peptidase 4 Homo sapiens 7-12 21437074-3 2010 This review summarizes experiences with DPP-4 inhibition in the treatment of type 2 diabetes, with a focus on sitagliptin. Sitagliptin Phosphate 110-121 dipeptidyl peptidase 4 Homo sapiens 40-45 20519186-0 2010 [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. Sitagliptin Phosphate 70-81 dipeptidyl peptidase 4 Homo sapiens 52-57 20519186-3 2010 Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes. Sitagliptin Phosphate 50-61 dipeptidyl peptidase 4 Homo sapiens 0-22 20519186-3 2010 Dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin demonstrate an incretin based, glucose-dependent actions with low risk of hypoglycemia and no weight gain during the treatment of patients with type 2 diabetes. Sitagliptin Phosphate 50-61 dipeptidyl peptidase 4 Homo sapiens 24-29 20462426-1 2010 Sitagliptin is a dipeptidyl peptidase-4 (DPP IV, CD26) inhibitor indicated for treatment of Type II diabetes as a second line therapy after metformin. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 17-39 20462426-1 2010 Sitagliptin is a dipeptidyl peptidase-4 (DPP IV, CD26) inhibitor indicated for treatment of Type II diabetes as a second line therapy after metformin. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 41-47 20462426-1 2010 Sitagliptin is a dipeptidyl peptidase-4 (DPP IV, CD26) inhibitor indicated for treatment of Type II diabetes as a second line therapy after metformin. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 49-53 20463416-8 2010 In randomized clinical trials, the DPP-4 inhibitors saxagliptin and sitagliptin reduced HbA1c by 0.5% to 0.8%, compared with placebo, whether used as monotherapy or in combination with another agent. Sitagliptin Phosphate 68-79 dipeptidyl peptidase 4 Homo sapiens 35-40 20412573-1 2010 BACKGROUND: In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated compared with treatment with control agents. Sitagliptin Phosphate 152-163 dipeptidyl peptidase 4 Homo sapiens 167-189 20380648-8 2010 The glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide and the dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin and vildagliptin effectively lower HbA1c; exenatide and liraglutide reduce weight and blood pressure and improve lipid profiles. Sitagliptin Phosphate 130-141 dipeptidyl peptidase 4 Homo sapiens 88-110 20380648-8 2010 The glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide and the dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin and vildagliptin effectively lower HbA1c; exenatide and liraglutide reduce weight and blood pressure and improve lipid profiles. Sitagliptin Phosphate 130-141 dipeptidyl peptidase 4 Homo sapiens 112-117 20380653-0 2010 Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 32-37 20380653-1 2010 AIM: To examine the effects of 12 weeks of treatment with the DPP-4 inhibitor, sitagliptin, on gastrointestinal hormone responses to a standardized mixed meal and beta cell secretory capacity, measured as glucose and non-glucose induced insulin secretion during a hyperglycaemic clamp, in patients with type 2 diabetes. Sitagliptin Phosphate 79-90 dipeptidyl peptidase 4 Homo sapiens 62-67 20332588-0 2010 Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Sitagliptin Phosphate 25-36 dipeptidyl peptidase 4 Homo sapiens 40-62 20205490-1 2010 Sitagliptin (Januvia, Glactiv(R), Tesavel(R)) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 51-73 20206729-6 2010 Sitagliptin inhibits the DPP-4 enzyme, thus increasing the half-life of endogenous GLP-1. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-30 20075143-0 2010 DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Sitagliptin Phosphate 20-31 dipeptidyl peptidase 4 Homo sapiens 0-5 20075143-2 2010 The active amide GLP-1 (7-36) is degraded by the enzyme DPP-4, and drugs that inhibit this enzyme (such as sitagliptin) have been introduced to treat type 2 diabetes. Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 56-61 20411816-1 2010 Sitagliptin (Januvia), the first selective inhibitor of dipeptidylpeptidase-4, has been assessed in a large Belgian prospective observational study. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 56-77 20519806-2 2010 Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, increase active GLP-1 and GIP levels and improve hyperglycemia in a glucose-dependent fashion. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 0-22 20519806-2 2010 Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, increase active GLP-1 and GIP levels and improve hyperglycemia in a glucose-dependent fashion. Sitagliptin Phosphate 51-62 dipeptidyl peptidase 4 Homo sapiens 24-29 20332588-1 2010 Sitagliptin is an oral, potent, highly selective, once-daily DPP-4 inhibitor indicated for the treatment of type 2 diabetes mellitus (T2DM). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 61-66 19748065-2 2009 The first available DPP-4 inhibitors are sitagliptin and vildagliptin. Sitagliptin Phosphate 41-52 dipeptidyl peptidase 4 Homo sapiens 20-25 19947817-3 2009 Data from clinical trials in which liraglutide, exenatide, saxagliptin, or sitagliptin were employed as monotherapy or added to ongoing antidiabetic treatment indicate that the incretin-based therapies have very low risk for the development of hypoglycemia and either decrease body weight (GLP-1-receptor agonists) or are weight neutral (DPP-4 inhibitors). Sitagliptin Phosphate 75-86 dipeptidyl peptidase 4 Homo sapiens 338-343 19900195-5 2009 Dipeptidyl peptidase-4 inhibitors, for example sitagliptin, have a modest effect on A1c levels (-0.7%) as monotherapy; however, they reduce A1c to a greater extent when combined with metformin ( approximately 2.0%). Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 0-22 19691426-0 2009 Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 35-40 19691426-1 2009 OBJECTIVE: In clinical trials, the degree of glucose lowering with sitagliptin has been correlated with the magnitude of dipeptidyl peptidase-4 (DPP-4) inhibition over 24 h. Previous studies evaluating sitagliptin doses ranging from 25 to 200 mg/day demonstrated that the daily dose of 100 mg provided maximal glucose-lowering efficacy for this compound in patients with type 2 diabetes. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 121-143 19691426-1 2009 OBJECTIVE: In clinical trials, the degree of glucose lowering with sitagliptin has been correlated with the magnitude of dipeptidyl peptidase-4 (DPP-4) inhibition over 24 h. Previous studies evaluating sitagliptin doses ranging from 25 to 200 mg/day demonstrated that the daily dose of 100 mg provided maximal glucose-lowering efficacy for this compound in patients with type 2 diabetes. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 145-150 19691426-1 2009 OBJECTIVE: In clinical trials, the degree of glucose lowering with sitagliptin has been correlated with the magnitude of dipeptidyl peptidase-4 (DPP-4) inhibition over 24 h. Previous studies evaluating sitagliptin doses ranging from 25 to 200 mg/day demonstrated that the daily dose of 100 mg provided maximal glucose-lowering efficacy for this compound in patients with type 2 diabetes. Sitagliptin Phosphate 202-213 dipeptidyl peptidase 4 Homo sapiens 145-150 19691426-2 2009 However, sitagliptin 200 mg once daily provided numerically greater percent plasma DPP-4 inhibition compared with 100 mg once daily. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 83-88 19743938-4 2009 These drugs include the glucagon-like peptide (GLP-1) agonists, exenatide, and dipeptidyl peptidase (DPP-IV) inhibitors such as sitagliptin and saxagliptin. Sitagliptin Phosphate 128-139 dipeptidyl peptidase 4 Homo sapiens 101-107 19783710-1 2009 Sitagliptin is an orally active, highly selective dipeptidyl peptidase IV (DPP-4) inhibitor for treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 50-73 19783710-1 2009 Sitagliptin is an orally active, highly selective dipeptidyl peptidase IV (DPP-4) inhibitor for treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 75-80 19545590-9 2009 In addition to incretin mimetics incretin enhancers which inhibit/delay degradation of incretins were developed: so-called DPP-4 inhibitors such as sitagliptin and vildagliptin are approved in Europe. Sitagliptin Phosphate 148-159 dipeptidyl peptidase 4 Homo sapiens 123-128 19780719-3 2009 DPP-4 inhibitors (alogliptin, saxagliptin, sitagliptin and vildagliptin) correct the GLP-1 deficiency by blocking this degradation, prolonging the incretin effect and enhancing glucose homoeostasis. Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 0-5 19476471-1 2009 AIMS: To develop predictive formulas using short-term changes in glycaemic parameters [haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG)] with sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, to assess longer term steady-state changes in HbA1c. Sitagliptin Phosphate 150-161 dipeptidyl peptidase 4 Homo sapiens 182-204 19602719-0 2009 A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 60-64 20298625-6 2010 According to these studies, the DPP-4 inhibitors sitagliptin and vildagliptin gave a mean HbA1c reduction of 0.7% and 0.6% respectively. Sitagliptin Phosphate 49-60 dipeptidyl peptidase 4 Homo sapiens 32-37 19952298-7 2009 DPP-4 inhibitors such as sitagliptin and saxagliptin increase endogenous GLP-1 concentration and demonstrate incretin-associated glucoregulatory actions in patients with T2DM. Sitagliptin Phosphate 25-36 dipeptidyl peptidase 4 Homo sapiens 0-5 19149538-3 2009 Various classes of structurally different DPP IV inhibitors are currently being explored and few of them such as Sitagliptin and Vildagliptin were successfully launched. Sitagliptin Phosphate 113-124 dipeptidyl peptidase 4 Homo sapiens 42-48 19507853-1 2009 A highly efficient synthesis of sitagliptin, a potent and selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM), has been developed. Sitagliptin Phosphate 32-43 dipeptidyl peptidase 4 Homo sapiens 68-73 21437116-5 2009 The first DPP-IV inhibitor approved in the United States was sitagliptin. Sitagliptin Phosphate 61-72 dipeptidyl peptidase 4 Homo sapiens 10-16 19259628-0 2009 DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Sitagliptin Phosphate 22-33 dipeptidyl peptidase 4 Homo sapiens 0-4 19330494-6 2009 These can mainly be divided into two broad categories; GLP-1 agonists/analogs (exenatide, liraglutide), and dipeptidyl peptidase-4 (DPP-4; the enzyme responsible for rapid inactivation of incretins) inhibitors (sitagliptin, vildagliptin). Sitagliptin Phosphate 211-222 dipeptidyl peptidase 4 Homo sapiens 108-130 19330494-6 2009 These can mainly be divided into two broad categories; GLP-1 agonists/analogs (exenatide, liraglutide), and dipeptidyl peptidase-4 (DPP-4; the enzyme responsible for rapid inactivation of incretins) inhibitors (sitagliptin, vildagliptin). Sitagliptin Phosphate 211-222 dipeptidyl peptidase 4 Homo sapiens 132-137 19275548-6 2009 The other group comprises the gliptins (e.g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 141-163 19275548-6 2009 The other group comprises the gliptins (e.g. sitagliptin and vildagliptin) which boost endogenous incretin activity by inhibiting the enzyme dipeptidyl peptidase 4 (DPP 4) that degrades both GLP-1 and GIP. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 165-170 19236626-0 2009 Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1). Sitagliptin Phosphate 54-65 dipeptidyl peptidase 4 Homo sapiens 38-43 19221403-1 2009 BACKGROUND: Sitagliptin is a highly selective dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 46-68 19182763-10 2009 DPP-4 inhibitors (e.g. sitagliptin, vindagliptin) prevent the degradation of endogenous GLP-1 and GIP, thereby potentiate their actions and help in glycemic control. Sitagliptin Phosphate 23-34 dipeptidyl peptidase 4 Homo sapiens 0-5 18513794-0 2009 Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure. Sitagliptin Phosphate 92-103 dipeptidyl peptidase 4 Homo sapiens 113-136 18755155-3 2008 During the pre-clinical and clinical evaluation of vildagliptin and sitagliptin, there has been a growing awareness of the presence of other DPP4-like peptidases in various cells and tissues. Sitagliptin Phosphate 68-79 dipeptidyl peptidase 4 Homo sapiens 141-145 19179812-8 2009 This article reviews data from a number of clinical trials, presentations, and abstracts indicating the importance of the DPP-4 inhibitors sitagliptin, vildagliptin, and alogliptin both alone and in combination with insulin sensitizers in the treatment of type 2 diabetes. Sitagliptin Phosphate 139-150 dipeptidyl peptidase 4 Homo sapiens 122-127 19179813-6 2009 In addition to reducing HbA1c and fasting plasma glucose, the recently developed diabetes therapies GLP-1 receptor agonists (eg, exenatide, liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (eg, sitagliptin, vildagliptin) appear to have beneficial effects on beta-cell dysfunction and, possibly, on alpha-cell dysregulation. Sitagliptin Phosphate 204-215 dipeptidyl peptidase 4 Homo sapiens 181-186 18476982-0 2008 Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Sitagliptin Phosphate 10-21 dipeptidyl peptidase 4 Homo sapiens 25-47 19022515-2 2008 The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Sitagliptin Phosphate 87-98 dipeptidyl peptidase 4 Homo sapiens 69-74 19260377-7 2008 Two classes of incretin-based drugs have been developed: GLP-1 mimetics (exenatide and liraglutide) and DPP-IV inhibitors (sitagliptin and vildagliptin). Sitagliptin Phosphate 123-134 dipeptidyl peptidase 4 Homo sapiens 104-110 18476982-1 2008 PURPOSE: The purpose of this exploratory analysis was to assess the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on pancreatic beta-cell function using a model-based analysis. Sitagliptin Phosphate 78-89 dipeptidyl peptidase 4 Homo sapiens 93-115 18929237-8 2008 The authors conducted a literature search of various databases to identify the clinical trials involving the DPP inhibitors and concluded that the DPP-4 inhibitors, for example, sitagliptin and vildagliptin, are efficacious for managing diabetes as monotherapy or combination therapy. Sitagliptin Phosphate 178-189 dipeptidyl peptidase 4 Homo sapiens 147-152 18954434-1 2008 BACKGROUND: Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 44-66 30764059-3 2008 Sitagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide to facilitate glucose regulation in response to a meal. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 47-52 18769687-7 2008 The second class, the dipeptidyl peptidase-4 inhibitors (such as sitagliptin and vildagliptin) rely on production of endogenous GLP-1 and act by reducing its turnover. Sitagliptin Phosphate 65-76 dipeptidyl peptidase 4 Homo sapiens 22-44 18628530-3 2008 Two new drugs, exenatide (GLP-1 mimetic) and sitagliptin [dipeptidyl peptidase (DPP) 4 inhibitor], have been approved by regulatory agencies for treating T2DM. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 58-86 19017837-3 2008 In the last 5 years new glucose lowering drugs acting on novel pathways have been developed, licensed and launched, such as the glucagon-like peptide (GLP-1) agonists (exenatide) and dipeptidyl peptidase (DPP-IV) inhibitors such as sitagliptin and vildagliptin. Sitagliptin Phosphate 232-243 dipeptidyl peptidase 4 Homo sapiens 205-211 18503607-1 2008 AIMS: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an incretin enhancer that is approved for the treatment of Type 2 diabetes. Sitagliptin Phosphate 6-17 dipeptidyl peptidase 4 Homo sapiens 21-43 18542012-5 2008 The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects. Sitagliptin Phosphate 64-75 dipeptidyl peptidase 4 Homo sapiens 21-43 18600568-4 2008 This strategy has resulted in the launch of two DPP-IV inhibitor drugs; sitagliptin in North America, several European territories, and various other countries, and vildagliptin in the EU as well as various countries. Sitagliptin Phosphate 72-83 dipeptidyl peptidase 4 Homo sapiens 48-54 18518780-1 2008 BACKGROUND: Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 51-73 18795210-11 2008 DPP-4 inhibitors such as sitagliptin and vildagliptin result in clinically significant reductions in HbA1c, and are weight neutral with few GI side effects. Sitagliptin Phosphate 25-36 dipeptidyl peptidase 4 Homo sapiens 0-5 18435673-1 2008 OBJECTIVE: Sitagliptin is a novel oral incretin enhancer that acts by inhibiting the dipeptidyl peptidase 4 enzyme and is indicated in Europe as a treatment adjunct to metformin (MF), sulphonylurea (SU), MF plus SU and diet and exercise, in the management of type 2 diabetes mellitus. Sitagliptin Phosphate 11-22 dipeptidyl peptidase 4 Homo sapiens 85-107 18577160-4 2008 A number of new therapeutic agents are undergoing clinical development, including glucagon-like peptide 1 mimetics (exenatide and liraglutide) and dipeptidyl peptidase 4 inhibitors (sitagliptin and vildagliptin), which target the incretin system, and the cannabinoid-1 receptor antagonists (rimonabant), which target the endocannabinoid system, may hold some promise for meeting these unmet needs. Sitagliptin Phosphate 182-193 dipeptidyl peptidase 4 Homo sapiens 147-169 18443229-11 2008 Sitagliptin, by blocking dipeptidyl peptidase IV, prevents metabolism of neuropeptide Y(1-36) and thereby increases the effects of neuropeptide Y(1-36) released from renal sympathetic nerves on Y(1) receptors leading to augmentation of neuropeptide Y(1-36)-induced enhancement of the renovascular effects of angiotensin II. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-48 18353996-0 2008 Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. Sitagliptin Phosphate 10-21 dipeptidyl peptidase 4 Homo sapiens 25-47 18519840-5 2008 Sitagliptin phosphate (a dipeptidyl peptidase IV inhibitor, 50 mg/d) was added to the treatment regimen to improve glycemic control. Sitagliptin Phosphate 0-21 dipeptidyl peptidase 4 Homo sapiens 25-48 18353996-1 2008 The effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on ambulatory blood pressure was assessed in nondiabetic patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, 3-period crossover study. Sitagliptin Phosphate 14-25 dipeptidyl peptidase 4 Homo sapiens 29-51 18498926-0 2008 Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-21 dipeptidyl peptidase 4 Homo sapiens 25-30 18425967-2 2008 One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. Sitagliptin Phosphate 123-134 dipeptidyl peptidase 4 Homo sapiens 76-98 18425967-2 2008 One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. Sitagliptin Phosphate 123-134 dipeptidyl peptidase 4 Homo sapiens 100-105 18425967-18 2008 All published randomised controlled trials of at least 12 weeks treatment with sitagliptin and vildagliptin only reported routine laboratory safety measurements AUTHORS" CONCLUSIONS: DPP-4 inhibitors have some theoretical advantages over existing therapies with oral antidiabetic compounds but should currently be restricted to individual patients. Sitagliptin Phosphate 79-90 dipeptidyl peptidase 4 Homo sapiens 183-188 18512528-5 2008 Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4 (DPP-4), which breaks down GLP-I. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 42-64 18512528-5 2008 Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4 (DPP-4), which breaks down GLP-I. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 66-71 17939170-1 2008 A sensitive high-performance liquid chromatography-positive ion electrospray tandem mass spectrometry method was developed and validated for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma. Sitagliptin Phosphate 163-174 dipeptidyl peptidase 4 Homo sapiens 178-183 18182122-2 2008 There are numerous DPP-4 inhibitors in development with sitagliptin as the first approved agent for the treatment of patients with type 2 diabetes. Sitagliptin Phosphate 56-67 dipeptidyl peptidase 4 Homo sapiens 19-24 18182122-6 2008 FINDINGS: Sitagliptin, an oral, once-daily, and highly selective DPP-4 inhibitor, has been evaluated in clinical trials as monotherapy, as add-on therapy, or as initial combination therapy with metformin. Sitagliptin Phosphate 10-21 dipeptidyl peptidase 4 Homo sapiens 65-70 18640590-2 2008 Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA(1c) (absolute values) by 0.5-1.1% (5 to 12%, relative values), with few adverse events and no weight gain. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 20-25 18319497-2 2008 SUMMARY: Sitagliptin is a dipeptidyl-peptidase IV (DPP4) inhibitor that increases insulin release and decreases glucagon levels by preventing the activation of incretin hormones--glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 26-49 18319497-2 2008 SUMMARY: Sitagliptin is a dipeptidyl-peptidase IV (DPP4) inhibitor that increases insulin release and decreases glucagon levels by preventing the activation of incretin hormones--glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 51-55 18319497-10 2008 CONCLUSION: Sitagliptin, a DPP4 inhibitor, offers a novel treatment option for patients with type 2 diabetes mellitus. Sitagliptin Phosphate 12-23 dipeptidyl peptidase 4 Homo sapiens 27-31 17939170-0 2008 Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. Sitagliptin Phosphate 90-101 dipeptidyl peptidase 4 Homo sapiens 105-110 18182122-0 2008 Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 17933414-1 2008 Efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 inhibitor, were assessed in Japanese patients with type 2 diabetes. Sitagliptin Phosphate 29-40 dipeptidyl peptidase 4 Homo sapiens 44-66 18372550-1 2008 Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 59-80 18840004-12 2008 The DPP-4 inhibitors sitagliptin and vildagliptin are generally weight neutral, with less marked gastrointestinal adverse effects than the GLP-1 receptor agonists. Sitagliptin Phosphate 21-32 dipeptidyl peptidase 4 Homo sapiens 4-9 18947259-12 2008 Clinical evidence suggests that the DPP-4 inhibitors vildagliptin and sitagliptin are particularly suitable for frail and debilitated elderly patients because of their excellent tolerability profiles. Sitagliptin Phosphate 70-81 dipeptidyl peptidase 4 Homo sapiens 36-41 17981665-6 2008 A number of clinical trials have demonstrated that DPP IV inhibitors are effective in improving glucose disposal and reducing hemoglobin A1c levels in type 2 diabetic patients and one inhibitor, sitagliptin, is now in therapeutic use, with others likely to receive FDA approval in the near future. Sitagliptin Phosphate 195-206 dipeptidyl peptidase 4 Homo sapiens 51-57 30743780-4 2008 Sitagliptin, a once-daily, orally active, competitive and fully reversible inhibitor of DPP-4, was, as first in its class, introduced to the market as Januvia . Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 88-93 19065992-6 2008 Sitagliptin, the first commercially available dipeptidyl peptidase-4 inhibitor, inhibits the metabolism and inactivation of the incretin hormones GLP-1 and GIP. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 46-68 19065993-7 2008 The overall risk profile of DPP-4 inhibitors was low, however a 34% relative risk increase (95% confidence interval 10% to 64%, P = 0.004) was noted for all-cause infection associated with sitagliptin use. Sitagliptin Phosphate 189-200 dipeptidyl peptidase 4 Homo sapiens 28-33 18561513-2 2008 Most clinical experience with DPP-4 inhibition is based on vildagliptin (GalvusR, Novartis) and sitagliptin (JanuviaR, Merck). Sitagliptin Phosphate 96-107 dipeptidyl peptidase 4 Homo sapiens 30-35 18201579-0 2007 Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-21 dipeptidyl peptidase 4 Homo sapiens 25-30 18201579-1 2007 BACKGROUND: Sitagliptin phosphate, the first dipeptidyl peptidase 4 (DPP-4) inhibitor, provides a new treatment option for patients with type 2 diabetes. Sitagliptin Phosphate 12-33 dipeptidyl peptidase 4 Homo sapiens 45-67 18201579-1 2007 BACKGROUND: Sitagliptin phosphate, the first dipeptidyl peptidase 4 (DPP-4) inhibitor, provides a new treatment option for patients with type 2 diabetes. Sitagliptin Phosphate 12-33 dipeptidyl peptidase 4 Homo sapiens 69-74 18201579-6 2007 RESULTS: By inhibiting DPP-4, sitagliptin enhances postprandial levels of active glucagon-like peptide-1 (GLP-1), leading to a rise in insulin release and decrease in glucagon secretion from pancreatic alpha-cells. Sitagliptin Phosphate 30-41 dipeptidyl peptidase 4 Homo sapiens 23-28 19337535-1 2008 Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme that normally inactivates incretin hormones. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 142-164 19337535-1 2008 Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme that normally inactivates incretin hormones. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 166-171 18217246-3 2007 When used in combination with metformin, sulfonylureas, or TZDs, GLP-1 analogs such as exenatide and DPP-IV inhibitors such as sitagliptin reduce A1C, fasting glucose levels, and postprandial glucose levels with few additional adverse events. Sitagliptin Phosphate 127-138 dipeptidyl peptidase 4 Homo sapiens 101-107 18632049-1 2007 Sitagliptin (brand name Januvia) the first of a new class of oral agents, the DPP4 inhibitors, which lower blood glucose in type 2 diabetes has recently been launched in UK. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 78-82 18174966-0 2007 Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 32-37 18174966-6 2007 Sitagliptin, a DPP-4 inhibitor, is orally active and has been shown to be efficacious and safe in clinical studies. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 18174966-8 2007 Like other DPP-4 inhibitors, sitagliptin reduces hemoglobin A1c (HbA1c), fasting and postprandial glucose by glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion. Sitagliptin Phosphate 29-40 dipeptidyl peptidase 4 Homo sapiens 11-16 17571284-0 2007 Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Sitagliptin Phosphate 45-56 dipeptidyl peptidase 4 Homo sapiens 78-100 18072437-0 2007 [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin]. Sitagliptin Phosphate 86-97 dipeptidyl peptidase 4 Homo sapiens 69-75 18072437-1 2007 Sitagliptin, distributed under the brand name of Januvia, has been the first and so far the only dipeptidyl peptidase IV (DPP-IV) inhibitor introduced in clinical practice. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 97-120 18072437-1 2007 Sitagliptin, distributed under the brand name of Januvia, has been the first and so far the only dipeptidyl peptidase IV (DPP-IV) inhibitor introduced in clinical practice. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 122-128 17987221-1 2007 Sitagliptin, a novel orally-active dipeptidyl-peptidase (DPP-4) inhibitor has been introduced into type 2 diabetes therapy. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 57-62 17575559-0 2007 Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Sitagliptin Phosphate 28-39 dipeptidyl peptidase 4 Homo sapiens 49-71 17575559-1 2007 The purpose of this study was to determine the absolute bioavailability of sitagliptin, an orally active, potent and highly selective dipeptidyl peptidase-4 inhibitor recently approved in the United States for the treatment of type 2 diabetes. Sitagliptin Phosphate 75-86 dipeptidyl peptidase 4 Homo sapiens 134-156 17571284-1 2007 Sitagliptin is a highly selective orally active dipeptidyl peptidase-4 inhibitor recently approved in the United States for the treatment of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 48-70 17593236-0 2007 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Sitagliptin Phosphate 61-72 dipeptidyl peptidase 4 Homo sapiens 27-49 17593236-1 2007 AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 115-137 17593236-1 2007 AIM: To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin. Sitagliptin Phosphate 67-78 dipeptidyl peptidase 4 Homo sapiens 139-144 17468348-0 2007 Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Sitagliptin Phosphate 57-68 dipeptidyl peptidase 4 Homo sapiens 72-94 17593275-5 2007 Newer agents based on enhancing incretin activity, including the glucagon-like peptide-1 mimetics exenatide and liraglutide and the oral dipeptidyl peptidase-4 inhibitors sitagliptin and vildagliptin, may offer particular advantages in elderly patients with diabetes. Sitagliptin Phosphate 171-182 dipeptidyl peptidase 4 Homo sapiens 137-159 17559747-8 2007 Initial clinical trial experience with the new oral DPP-4 inhibitors such as sitagliptin and vildagliptin suggests that these agents are weight-neutral, while providing improved glycaemic control when added to metformin. Sitagliptin Phosphate 77-88 dipeptidyl peptidase 4 Homo sapiens 52-57 17559747-10 2007 Initial clinical trial experience with oral DPP-4 inhibitors such as sitagliptin and vildagliptin suggest that these agents may represent an important oral treatment option for weight-neutral, glycaemic control when added to metformin. Sitagliptin Phosphate 69-80 dipeptidyl peptidase 4 Homo sapiens 44-49 17848846-7 2007 The oral DPP-4 inhibitors vildagliptin, sitagliptin, and saxagliptin are efficacious both alone and in association with other oral anti-diabetic agents and may be administered in a single daily dose. Sitagliptin Phosphate 40-51 dipeptidyl peptidase 4 Homo sapiens 9-14 17541529-4 2007 In April 2007, the first members of the GLP 1 analogues/incretin mimetics (exenatide, Byetta) and DPP 4 inhbitors (sitagliptin, Januvia) have become available for the treatment of type 2 diabetes in Germany. Sitagliptin Phosphate 115-126 dipeptidyl peptidase 4 Homo sapiens 98-103 17314201-0 2007 Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. Sitagliptin Phosphate 50-61 dipeptidyl peptidase 4 Homo sapiens 17-39 17433672-0 2007 Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. Sitagliptin Phosphate 158-169 dipeptidyl peptidase 4 Homo sapiens 76-81 17433672-2 2007 The X-ray crystal structure of sitagliptin bound to DPP-4 suggested that the central beta-amino butyl amide moiety could be replaced with a cyclohexylamine group. Sitagliptin Phosphate 31-42 dipeptidyl peptidase 4 Homo sapiens 52-57 17434732-0 2007 Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). Sitagliptin Phosphate 82-89 dipeptidyl peptidase 4 Homo sapiens 29-52 17434732-0 2007 Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). Sitagliptin Phosphate 91-112 dipeptidyl peptidase 4 Homo sapiens 29-52 17559733-0 2007 Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Sitagliptin Phosphate 11-22 dipeptidyl peptidase 4 Homo sapiens 26-48 17559733-1 2007 OBJECTIVE: Sitagliptin, an oral, potent, and selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated as once-daily monotherapy in a 12-week randomized, double-blind, placebo-controlled, parallel group, dose-ranging study. Sitagliptin Phosphate 11-22 dipeptidyl peptidase 4 Homo sapiens 55-77 17559733-1 2007 OBJECTIVE: Sitagliptin, an oral, potent, and selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated as once-daily monotherapy in a 12-week randomized, double-blind, placebo-controlled, parallel group, dose-ranging study. Sitagliptin Phosphate 11-22 dipeptidyl peptidase 4 Homo sapiens 79-84 17392725-0 2007 Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 0-22 17392725-3 2007 This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes. Sitagliptin Phosphate 121-132 dipeptidyl peptidase 4 Homo sapiens 105-110 17314201-1 2007 Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor recently approved for the treatment of type 2 diabetes, is excreted into the urine via active tubular secretion and glomerular filtration in humans. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 25-47 17353295-21 2007 In preclinical studies, oral active DPP-IV inhibitors (sitagliptin and vildagliptin) also promoted beta-cell proliferation, neogenesis, and inhibition of apoptosis in rodents. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 36-42 17220239-0 2007 Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Sitagliptin Phosphate 70-81 dipeptidyl peptidase 4 Homo sapiens 32-54 17300591-5 2007 DPP-IV inhibitors such as vildagliptin and sitagliptin have been shown to be highly effective antihyperglycaemic agents that augment insulin secretion and reduce glucagon secretion via glucose-dependent mechanisms. Sitagliptin Phosphate 43-54 dipeptidyl peptidase 4 Homo sapiens 0-6 17371200-0 2007 Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Sitagliptin Phosphate 39-50 dipeptidyl peptidase 4 Homo sapiens 0-22 17371200-1 2007 Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 90-112 17300594-1 2007 AIM: The aim of this study was to assess the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on 24-h glucose control when added to the regimen of patients with type 2 diabetes who had inadequate glycaemic control on metformin therapy. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 70-92 17300595-0 2007 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Sitagliptin Phosphate 61-72 dipeptidyl peptidase 4 Homo sapiens 27-49 17300594-0 2007 Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Sitagliptin Phosphate 17-28 dipeptidyl peptidase 4 Homo sapiens 32-54 17244766-1 2007 Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an incretin enhancer that is approved for the treatment of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-37 17244767-0 2007 Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. Sitagliptin Phosphate 76-87 dipeptidyl peptidase 4 Homo sapiens 101-123 17244767-1 2007 Sitagliptin (MK-0431) is an orally active, potent, and selective dipeptidyl peptidase-4 inhibitor used for the treatment of patients with type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 65-87 17244767-1 2007 Sitagliptin (MK-0431) is an orally active, potent, and selective dipeptidyl peptidase-4 inhibitor used for the treatment of patients with type 2 diabetes mellitus. Sitagliptin Phosphate 13-20 dipeptidyl peptidase 4 Homo sapiens 65-87 17156104-0 2007 Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Sitagliptin Phosphate 66-77 dipeptidyl peptidase 4 Homo sapiens 33-55 17379930-11 2007 Clinical studies with the oral DPPIV inhibitors sitagliptin and vildagliptin show promising results, but are only published as abstracts at scientific meetings. Sitagliptin Phosphate 48-59 dipeptidyl peptidase 4 Homo sapiens 31-36 17352516-1 2007 Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 45-50 17352516-1 2007 Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 104-109 17315049-0 2007 Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 32-37 17315049-6 2007 Sitagliptin, a DPP-4 inhibitor, is orally active and has been shown to be efficacious and safe in clinical studies. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-20 17315049-8 2007 Like other DPP-4 inhibitors, sitagliptin reduces hemoglobin A1c (HbA1c), fasting and postprandial glucose by glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion. Sitagliptin Phosphate 29-40 dipeptidyl peptidase 4 Homo sapiens 11-16 17352516-1 2007 Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 21-43 17156104-1 2007 The aim of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise. Sitagliptin Phosphate 107-118 dipeptidyl peptidase 4 Homo sapiens 73-95 17580730-1 2007 Sitagliptin (Januvia, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 82-87 17580730-1 2007 Sitagliptin (Januvia, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Sitagliptin Phosphate 13-20 dipeptidyl peptidase 4 Homo sapiens 82-87 16912128-0 2006 Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Sitagliptin Phosphate 31-42 dipeptidyl peptidase 4 Homo sapiens 46-68 17130196-0 2006 Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Sitagliptin Phosphate 47-58 dipeptidyl peptidase 4 Homo sapiens 14-36 17130197-0 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 27-49 17130197-1 2006 OBJECTIVE: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA(1c) [A1C] >or=7 and <or=10%) with metformin alone. Sitagliptin Phosphate 76-87 dipeptidyl peptidase 4 Homo sapiens 42-64 17098089-5 2006 Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA1c by 0.5-1.0%, with few adverse events and no weight gain. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 20-25 16912128-11 2006 RESULTS: Sitagliptin dose-dependently inhibited plasma DPP-4 activity over 24 h, enhanced active GLP-1 and GIP levels, increased insulin/C-peptide, decreased glucagon, and reduced glycemic excursion after OGTTs administered at 2 and 24 h after single oral 25- or 200-mg doses of sitagliptin. Sitagliptin Phosphate 9-20 dipeptidyl peptidase 4 Homo sapiens 55-60 16912128-13 2006 CONCLUSIONS: In this study in patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitagliptin concentration of 100 nm or greater, and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT. Sitagliptin Phosphate 103-114 dipeptidyl peptidase 4 Homo sapiens 180-185 16855072-0 2006 Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 57-62 17157112-0 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Sitagliptin Phosphate 60-71 dipeptidyl peptidase 4 Homo sapiens 27-49 17157112-1 2006 OBJECTIVE: The efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy were assessed in patients with type 2 diabetes and inadequate glycemic control (glycosylated hemoglobin [HbA(1c)] > or =7% and < or =10%) while receiving a stable dose of pioglitazone. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 48-70 17022853-0 2006 Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Sitagliptin Phosphate 88-99 dipeptidyl peptidase 4 Homo sapiens 55-77 17022853-1 2006 OBJECTIVE: As part of the clinical development of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes, the potential for pharmacokinetic interactions with other antihyperglycemic agents used in managing patients with type 2 diabetes are being carefully evaluated. Sitagliptin Phosphate 50-61 dipeptidyl peptidase 4 Homo sapiens 65-87 16855072-5 2006 Sitagliptin treatment led to approximately 90% inhibition of plasma DPP-4 activity, increased active glucagon-like peptide-1 (GLP-1) levels by 2.7-fold (P < .001), and decreased post-oral glucose tolerance test glucose excursion by 35% (P < .050) compared to placebo. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 68-73 16855072-6 2006 In nondiabetic obese subjects, treatment with sitagliptin 200 mg bid was generally well tolerated without associated hypoglycemia and led to maximal inhibition of plasma DPP-4 activity, increased active GLP-1, and reduced glycemic excursion. Sitagliptin Phosphate 46-57 dipeptidyl peptidase 4 Homo sapiens 170-175 16855072-1 2006 Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 56-79 16855072-1 2006 Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 81-86 16855072-1 2006 Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes. Sitagliptin Phosphate 13-20 dipeptidyl peptidase 4 Homo sapiens 56-79 16855072-1 2006 Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes. Sitagliptin Phosphate 13-20 dipeptidyl peptidase 4 Homo sapiens 81-86 16868220-0 2006 Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 15-38 16868220-1 2006 OBJECTIVE: To review the pharmacology, pharmacokinetics, safety, and efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the management of type 2 diabetes mellitus. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 96-119 16868220-1 2006 OBJECTIVE: To review the pharmacology, pharmacokinetics, safety, and efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the management of type 2 diabetes mellitus. Sitagliptin Phosphate 81-92 dipeptidyl peptidase 4 Homo sapiens 121-127 16868220-5 2006 DATA SYNTHESIS: Sitagliptin is a potent, competitive, reversible inhibitor of the DPP-IV enzyme. Sitagliptin Phosphate 16-27 dipeptidyl peptidase 4 Homo sapiens 82-88 16490580-0 2006 Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Sitagliptin Phosphate 73-84 dipeptidyl peptidase 4 Homo sapiens 88-111 16682937-12 2006 DPP-4-inhibitors (e.g. Vildagliptin), Sitagliptin and Saxagliptin) that inhibit the enzyme DPP-4 responsible for incretin degradation are also under study. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 91-96 16490580-2 2006 Sitagliptin is an orally active and selective DPP-IV inhibitor currently in Phase III development for the treatment of type 2 diabetes mellitus. Sitagliptin Phosphate 0-11 dipeptidyl peptidase 4 Homo sapiens 46-52 16490580-17 2006 CONCLUSIONS: The results from this study in a select population of healthy male volunteers suggest that multiple oral doses of sitagliptin inhibited plasma DPP-IV activity and affected active GLP-1 concentrations in a dose-dependent manner, without producing hypoglycemia. Sitagliptin Phosphate 127-138 dipeptidyl peptidase 4 Homo sapiens 156-162 16338283-0 2005 Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Sitagliptin Phosphate 41-52 dipeptidyl peptidase 4 Homo sapiens 70-93 16338283-6 2005 Single doses of sitagliptin markedly and dose-dependently inhibited plasma DPP-IV activity, with approximately 80% or greater inhibition of DPP-IV activity occurring at 50 mg or greater over a 12-hour period and at 100 mg or greater over a 24-hour period. Sitagliptin Phosphate 16-27 dipeptidyl peptidase 4 Homo sapiens 75-81 16338283-6 2005 Single doses of sitagliptin markedly and dose-dependently inhibited plasma DPP-IV activity, with approximately 80% or greater inhibition of DPP-IV activity occurring at 50 mg or greater over a 12-hour period and at 100 mg or greater over a 24-hour period. Sitagliptin Phosphate 16-27 dipeptidyl peptidase 4 Homo sapiens 140-146 16338283-10 2005 By inhibiting plasma DPP-IV activity, sitagliptin increases the postprandial rise in active glucagon-like peptide 1 concentrations without causing hypoglycemia in normoglycemic healthy male volunteers. Sitagliptin Phosphate 38-49 dipeptidyl peptidase 4 Homo sapiens 21-27 17491680-13 2005 Dipeptidyl-peptidase IV inhibitors (DPP-IV inhibitors; e.g. Vildagliptin, Sitagliptin) that inhibit the enzyme responsible for incretin degradation are also under study. Sitagliptin Phosphate 74-85 dipeptidyl peptidase 4 Homo sapiens 36-42 16318402-13 2005 Dipeptidyl peptidase-IV inhibitors (e.g. vildagliptin, sitagliptin, and saxagliptin) that inhibit the enzyme responsible for incretin degradation are also being studied. Sitagliptin Phosphate 55-66 dipeptidyl peptidase 4 Homo sapiens 0-23